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SUMÁRIO1 
 
As células estaminais adultas obtidas a partir do estroma de tecidos humanos, 
representam uma fonte celular potencialmente atractiva para a terapia celular da 
Diabetes Mellitus. Todavia, não existem ainda resultados definitivos que permitam a 
sua aplicação clínica.  
Objectivos 
1. Avaliação do potencial de diferenciação endócrina das células estaminais 
mesenquimatosas humanas, imortalizadas pela telomerase (hMSC-TERT); 
2. Análise comparativa da plasticidade e assinatura molecular de células humanas 
derivadas do ilhéu pancreático (hIPC) e células estaminais mesenquimatosas derivadas 
da medula óssea (hBM-MSC). 
Estratégias de investigação 
1. Diferenciar in vitro as hMSC-TERT em células produtoras de insulina através de: 
a) Cultura em meio específico pró-endócrino; 
b) Expressão ectópica de dois genes reguladores do pâncreas endócrino humano, 
 neurogenina3 (hNGN3) e pancreatic-duodenal homeobox 1 (hPDX-1) nas 
 células hMSC-TERT.  
2. Comparar a assinatura molecular funcional das hIPC e hBM-MSC por:  
a) Caracterização do fenotipo imunológico; 
                                                 
1 Resumo até 300 palavras, de acordo com o artigo 40º do DR nº153, II série de 5 Julho de 2003 que 
regulamenta a elaboração das teses de doutoramento. 
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b) Diferenciação in vitro das hIPC e hBM-MSC em linhagens mesenquimatosas e 
 endócrinas; 
c) Análise transcripcional de marcadores do mesênquima e genes associados ao 
 carácter estaminal. Identificação de genes-alvo relacionados com a origem e 
 função das hIPC e hBM-MSC. 
Resultados 
As hMSC-TERT são diferenciáveis em fenótipos do pâncreas endócrino com 
capacidade de síntese de insulina. Tal como ocorre na pancreatogénese,  a  expressão de 
NGN3 contribui para a activação do PDX1 nas hMSC-TERT. A ausência de resposta 
insulínica à glicose indica que as hMSC-TERT modificadas não atingiram a maturidade 
funcional de células-beta nativas; 
As hIPC e hBM-MSC apresentam características de MSC, tendo todavia, funções 
tecidulares distintas que reflectem diferenças moleculares relacionadas com  a 
“especificidade mesodérmica” e “memória posicional” destas células. As hIPC, 
encontram-se num estado de transição epitelial-mesenquimatosa . 
Conclusões 
As populações MSC, são células estaminais adultas com níveis distintos de plasticidade 
e compromisso tecidular. Estudos futuros permitirão identificar as MSC com maior 
potencial para substituição ou regeneração de células beta na Diabetes tipo 1. 
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SUMMARY2 
Human adult mesenchymal stem cells (hMSC) represent a potential source for cell-
based therapies in Diabetes Mellitus. Yet, till now, no definitive data exist for clinical 
application. 
Aims 
1. Evaluation of the pancreatic endocrine differentiation potential of human-
mesenchymal stem-cells, immortalized with telomerase (hMSC-TERT); 
2. Comparative analysis of the plasticity and molecular signature of human-islet-derived 
pancreatic cells (hIPC) and bone-marrow-derived hMSC (hBM-MSC).  
Research strategies:  
1. In vitro differentiation of hMSC-TERT into insulin producing cells through: 
 a) Endocrine-promoting culture conditions; 
 b) Ectopic expression of two key regulatory genes of human endocrine pancreas, 
 neurogenin3 (hNGN3) and pancreatic-duodenal homeobox 1 (/hPDX-1) genes in 
 hMSC-TERT. 
2. Comparison of the functional signature of hIPC and hBM-MSC by: 
a) Immunophenotype characterization; 
b) In vitro mesenchymal and endocrine differentiation of primary hBM-MSC and 
 hIPC; 
 
 
                                                 
2 Abstract up to 300 words, in accordance with the 40th article of DR nº153, II series of 
5th of July 2003, which regulates PhD thesis elaboration. 
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c) Transcriptome analysis for detection of mesenchymal and adult stem-cell related 
 gene markers. Identification of target genes, related to the origin and function of 
 hBM-MSC and hIPC. 
Results  
We could demonstrate that hMSC-TERT can be differentiated in vitro into pancreatic 
endocrine phenotypes with the ability to synthesise and store insulin. Similar to 
pancreatic development, in hMSC-TERT, NGN3 contributes to the activation of PDX-1 
promoter. Insulin secretion in a glucose-sensing manner was not detected in our cell 
system, which indicates that a mature state of beta-cell was not attained in these 
phenotypes; 
hIPC and hBM-MSC display very similar MSC phenotypes.  However, our data suggest 
distinct functions of these populations, which are related to a “mesodermal tissue 
specification” and “positional memory” of these cells. In hIPC, we confirmed a state of 
epithelial-mesenchymal transition. 
Conclusions 
MSC populations are adult stem cells with distinct levels of plasticity and commitment. 
Future studies will help to identify those MSC populations with greater potential to 
replace or regenerate beta cells in type 1 Diabetes.  
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PREFÁCIO 
A prática da Medicina sempre foi uma actividade em constante evolução e envolta de 
interrogações. Os doentes questionam acerca da doença, das suas causas, do tratamento 
e da existência ou não de cura. Os médicos, acerca do diagnóstico e das atitudes 
terapêuticas mais adequadas. Apesar das soluções que decorrem do conhecimento 
actualizado, da experiência e do senso clínico, a verdade é que para muitas perguntas 
não existem ainda respostas. Este facto justifica uma curiosidade constante na busca do 
conhecimento mais actual e consequentemente dos avanços da Ciência.  
Interroguei-me muitas vezes, se os médicos têm um papel devidamente relevante nos 
caminhos da investigação clínica e básica. Em particular, se esta última deverá ser uma 
área estritamente reservada a biólogos, químicos e outros profissionais das ciências 
básicas. 
Na verdade acredito que o treino diário do raciocínio clínico, baseado no  
relacionamento/associação de ideias, bem como a actualização do conhecimento através 
de bibliografia, palestras ou discussões com colegas, são ferramentas ideais para colocar 
as questões científicas mais adequadas e urgentes.   
Em muitos países a prátca médica corre a par com a investigação científica básica, 
tendo os médicos um papel decisivo nas linhas de investigação emergentes. 
Todas estas inquietações, associadas ao gosto pela pesquisa e uma curiosidade nunca 
satisfeita, conduziram-me, já numa fase sólida da carreira como Pediatra dedicada à 
Endocrinologia e Diabetologia Infantil, a investir na ciência directamente aplicada à 
Medicina.  
A ideia motivadora foi a de que a Diabetes tipo 1 (uma doença mortal até à descoberta 
da insulina em 1921) possa, de facto, vir a ter cura.  
PREFÁCIO 
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Tal como em muitas outras doenças degenerativas, as estratégias terapêuticas baseadas 
na substituição ou regeneração das células afectadas parecem ter um futuro prometedor 
na cura da Diabetes Mellitus. 
De facto, a terapia celular da Diabetes é já uma realidade através dos transplantes de 
ilhéus pancreáticos humanos. Contudo, o método é ainda ineficaz, a fonte celular 
humana é limitada e até hoje, a obtenção da cura definitiva ainda não foi possível. 
O objectivo último deste trabalho experimental  foi investigar outras fontes celulares 
passíveis de substituir a função do pâncreas endócrino lesado que pudessem ser 
transplantadas em doentes com Diabetes tipo1, de modo a atingir a independência 
insulínica. 
Este trajecto, árduo mas fascinante, tornou possível compreender melhor a 
complexidade molecular e funcional da célula beta do pâncreas. Permitiu aprofundar 
conceitos sobre  biologia do desenvolvimento. Estimulou a aquisição de conhecimentos 
recentes no campo da biologia dos tecidos adultos, no que respeita a vias de sinalização 
de morte e proliferação celular. Resultou, por fim, na identificação de células estaminais 
/ progenitoras com hierarquias de pluripotência, níveis de plasticidade e assinaturas 
moleculares distintas.  
Ainda que os resultados obtidos fiquem sempre aquém dos objectivos idealizados 
reconheço, no entanto, o valor inestimável dos conhecimentos adquiridos, 
nomeadamente: conceitos báscos de biologia molecular, genética e química; métodos 
laboratoriais avançados; formulação de hipóteses científicas; concepção de projectos de 
investigação e elaboração de artigos para revistas.  
Foi estimulante deparar, nesta área de investigação, com um nível deveras elevado de 
competitividade que obriga a ideias muitissimo inovadoras, eficiência no trabalho 
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experimental e rapidez na publicação dos resultados. Reunir estas condições não foi 
tarefa fácil para quem, como eu, estava no início desta actividade.  
Os resultados e conclusões de três anos de trabalho, exclusivamente laboratorial e as 
publicações daí resultantes, são o objecto desta tese de doutoramento.  
Como bolseira, devo um agradecimento à Sociedade Europeia de Endocrinologia 
Pediátrica, pela possiblidade de, durante dois anos, ter podido desenvolver as ideias e 
linhas de investigação necessárias para este projecto, num centro europeu conceituado. 
Devo o subsequente suporte para prosseguir os trabalhos, publicar os resultados e 
defender esta tese de doutoramento, à Fundação para a Ciência e Tecnologia, através de 
uma “Bolsa Individual de Doutoramento”. 
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RESUMO 
Introdução 
A Diabetes Mellitus é uma doença de elevada e crescente incidência com um grande 
impacto socioeconómico. As terapêuticas actualmente disponíveis, destinadas à 
normalização da glicémia, se bem que razoavelmente eficazes e largamente utilizadas, 
são exclusivamente sintomáticas. Surge pois a necessidade de actuar no primum movens 
da doença, com uma finalidade curativa, ou seja, regenerando ou substituindo as células 
lesadas dos ilhéus de Langerhans.    
As estratégias baseadas na terapêutica celular  são abordagens promissoras que visam a 
cura da Diabetes tipo 1 (DT1) bem como de formas avançadas de Diabetes tipo 2 
(DT2). Revelam, no entanto limitações; o transplante de ilhéus pancreáticos, por 
exemplo, tem tido um alcance limitado devido não só à escassez de orgãos de dadores 
mas também  por implicar uma imunosupressão prolongada. A investigação na área das 
células estaminais poderá permitir ultrapassar estes problemas quer pela geração de 
células produtoras de insulina passíveis de ser transplantadas quer pela regeneração de 
células beta a partir de células progenitoras existentes no organismo. 
Estudos de diferenciação de células estaminais embrionárias e células estaminais 
adultas em células fenotípicamente semelhantes às células beta do pâncreas endócrino 
mostraram-se bastante encorajadores. Assim, células estaminais mesenquimatosas 
(mesenchymal stem/stromal cells (MSC)) adultas obtidas a partir do estroma da medula 
óssea (hBM-MSC), representam uma possível fonte celular para a repovoação de 
células insulínicas uma vez que existem em abundância, são fáceis de obter e 
apresentam baixa imunogenecidade. Por outro lado, foi possível diferenciar 
determinadas células oriundas dos ductos, ácinos e ilhéus de Langerhans em células 
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produtoras de insulina. Destas células, têm particular interesse as isoladas a partir do 
ilhéu pancreático, comummente designadas de células progenitoras derivadas do ilhéu 
(Islet-derived Progenitor Cells (IPC)). As IPC têm sido alvo de intensa investigação, 
sobretudo no que respeita  à sua origem germinativa (epitelial ou mesenquimatosa) e à 
sua função nestes tecidos, nomeadamente ao seu carácter progenitor e potencial para 
substituir ou regenerar as células beta lesadas. 
Objectivos 
Neste estudo pretendeu-se estabelecer um modelo celular que permitisse avaliar de 
forma segura e reproduzível a capacidade de diferenciação das hBM-MSC em células 
produtoras de insulina, ultrapassando os problemas da variabilidade de dadores e da 
heterogeneidade de populações de MSC primárias.  
Um segundo objectivo consistiu em analisar a plasticidade e assinatura molecular das 
hIPC primárias de modo a determinar o seu potencial de substituição/ regeneração de 
células insulínicas e compará-las com as hBM-MSC.  
Métodos 
I. Diferenciação in vitro de hMSC-TERT em células produtoras de insulina 
a) Análise da linha celular humana de células estromais mesenquimatosas isoladas 
a partir da medula óssea de um índivíduo adulto saudável e  imortalizadas pela 
telomerase (hMSC-TERT)  no que respeita à expressão de dois genes 
marcadores de células estaminais, NESTINA e C-MET/HGFR, utilizando 
técnicas de RT-PCR, citometria de fluxo e imunocitoquímica. 
b) Cultura das hMSC-TERT em meio específico pró-endócrino durante 9 dias. 
Após este período de tempo, procedeu-se à análise da expressão de genes 
marcadores da diferenciação endócrina através de RT-PCR. 
RESUMO 
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c) Sobreexpressão nas hMSC-TERT de dois genes fundamentais para a 
diferenciação e funcionamento do pâncreas endócrino hNGN3 e/ou hPDX1, 
através de técnicas de lipotransfecção, de forma a obter três linhas celulares 
estáveis, nomeadamente hMSC-TERT-NGN3, hMSC-TERT-PDX1  e hMSC-
TERT-NGN3/PDX1. Seguidamente, procedeu-se à análise da expressão de 
genes específicos do ilhéu incluindo os PAX4, PAX6, NEUROD1, PDX1, 
GLUT2, GCK e INSULINA) através de RT-PCR. A síntese proteica de insulina e 
péptido-C, foram analisadas nestas linhas celulares por western-blotting e 
imunocitoquímica.  
d) Posteriormente, analisou-se a actividade funcional do hNGN3 e do PDX1 nas 
novas linhas celulares utilizando métodos de quantificação da actividade dos 
genes promotores/activadores do PDX1 e da Insulina, nomeadamente os ensaios 
SEAP e Luciferase. O conteúdo e secreção de insulina foram avaliados por um 
método ELISA. 
II. Comparação da assinatura molecular funcional das hIPC e hBM-MSC primárias 
e) Detecção dos marcadores de superfície hematopoiéticos (CD14, CD34, CD45) e 
mesenquimatosos (CD29, CD44, CD54, CD73, CD90 e CD105) em três dadores 
de hIPC (n=3) e e cinco de hBM-MSC (n=5)  através de citometria de fluxo. 
f) Cultura das hIPC e hBM-MSC em condições indutoras de diferenciação 
osteogénica, condrogénica e adipogénica de acordo com protocolos 
standardizados. Paralelamente, procedeu-se à cultura das células hIPC e hBM-
MSC em meios de diferenciação endócrina durante 5 dias. 
g) Análise de marcadores genéticos do mesênquima ( FNT, THY1, SNAI2, 
P4HA1, MMP2 e VIM ) e do pâncreas endócrino (p. ex. PAX4, PAX6, NGN3, 
NEUROD1, PDX1, GLUT2, GCK e INSULINA)  nas duas populações, por RT-
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PCR.  Detecção da síntese proteica de vimentina e insulina por  
imunocitoquímica de fluorescência. 
h) Determinação do perfil de expressão genómica das hIPC de três dadores e das 
hBM-MSC de 5 dadores, a partir do RNA total isolado destas amostras e 
utilizando técnicas de hibridização por microarray, nomeadamente Affymetrix 
Gene Chips HG-U133 Plus 2.0.  
i) Avaliação quantitativa do transcriptoma nos dois grupos  de células utilizando o 
método de análise de significância dos microarrays (significance analysis of 
microarrays (SAM)). Parte dos resultados obtidos pelos microarrays foi 
confirmada por RT-PCR.  
j) Identificação de genes alvo relacionados com a capacidade de diferenciação 
endócrina nas hIPC, utilizando a PCR em tempo real (qPCR).  
Resultados 
I. Diferenciação in vitro de hMSC-TERT em células produtoras de insulina 
A cultura das hMSC-TERT em meio pró-endócrino, assim como a expressão ectópica 
dos genes hNGN3 e hPDX1 induziram nestas células a expressão de genes 
anteriormente não expressados e relacionados com o pâncreas endócrino nomeadamente 
os PAX4,  PAX6 , NEUROD1, INSULINA, GLUT2, GLUCAGON e SOMATOSTATINA. 
 A sobreexpressão de NGN3 nas hMSC-TERT promoveu a expressão de NEUROD, 
PAX4 e PDX1, à semelhança da conhecida cascata de factores de transcrição observada 
na pancreatogénese. A expressão de PDX1 foi suficiente para desencadear o processo de 
diferenciação endócrina nas hMSC-TERT, o que sugere a existência de um 
“compromisso” endodérmico nesta população de células de origem mesodérmica.  
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As três novas linhas celulares hMSC-TERT geradas, mostraram capacidade de 
produção e secreção de insulina. No entanto, em nenhuma delas se detectou uma 
resposta insulínica sensível à concentração de glucose.  
II. Determinação da assinatura molecular funcional das hIPC e hBM-MSC primárias 
As células hIPC isoladas a partir do ilhéu pancreático e as células hBM-MSC oriundas 
da medula óssea, apresentam um fenótipo imunológico sobreponível entre si. 
A expressão de genes do core mesenquimatoso bem como a de genes associados a um 
carácter estaminal é significativa, tanto nas hIPC como nas hBM-MSC, sugerindo que 
ambos os tipos celulares apresentam um fenotipo característico de MSC. Contudo, as 
hIPC revelaram uma capacidade de diferenciação mesenquimatosa (osso, cartilagem e 
tecido adiposo) reduzida.  As hBM-MSC  por sua vez,  mostraram uma capacidade de 
diferenciação no sentido endócrino algo rudimentar.  
 A partir dos dados obtidos por microarray, procedeu-se a uma análise genética in silico 
(utilizando programas informáticos) dos grupos ontológicos importantes que veio 
confirmar o envolvimento das duas populações hIPC e hBM-MSC em processos 
biológicos distintos. Detectaram-se também diferenças significativas entre os dois tipos 
de células no que respeita ao padrão de expressão genética das cadherinas e dos factores 
de transcrição relacionados com as vias de diferenciação mesodérmicas e endodérmicas 
nomeadamente a família de genes HOX , os genes SOX17 e  ISL-1. 
Nas hIPC, em particular, verificou-se uma expressão significativa de genes relacionados 
com um estado de transição funcional celular (ex. genes TCF21, TGFb) que não se 
encontrou nas hBM-MSC. 
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Conclusões 
Concluí-se que nas hMSC-TERT é possível induzir a  activação de  genes-chave do 
pâncreas endócrino, bem como a  produção e secreção de insulina. Esta linha celular 
humana constitui assim um modelo adequado para a investigação de células 
mesenquimatosas derivadas da MO (hBM-MSC) como fonte de células-alternativas 
para substituição ou regeneração de células beta. No entanto, para que estas  hMSC 
possam vir a ser utilizadas na terapêutica celular da diabetes será necessário induzir um 
estado mais avançado de maturação endócrina. 
 O segundo estudo revelou que as hIPC são células com carácter mesenquimatoso 
oriundas da mesoderme mas que apresentam um fenótipo específico relacionado com o 
tecido em que residem, o ilhéu pancreático. Além do mais, estas células encontram-se 
num estado evidente de transição seja epitelio-mesenquimatosa (EMT)  ou 
mesenquimatosa- epitelial (MET) que corresponde a um estadio intermédio de 
diferenciação e as coloca numa posição priveligiada de “stand-by”.   
Será pois importante prosseguir este estudo de modo a compreender 1) se as hIPC são 
essenciais para a regeneração do ilhéu e 2) se é possível completar o seu estado de 
transição para um fenotipo endócrino maturo. 
 Os nossos estudos acrescentaram novos conhecimentos relativamente às características 
moleculares das populações MSC presentes em diferentes tecidos e à sua potencial 
aplicação em estratégias de terapêutica celular da DT1.      
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ABSTRACT 
Background 
Diabetes Mellitus is a disease of increasing incidence, with important socioeconomic 
impact. So far, all available therapies have been directed to normalize glycemic level.  
Although effective, they only minimize symptoms, as well as preventing or delaying 
long-term vascular complications .Therefore, new approaches acting at the primum 
movens of the disease urge to be developed. 
Cell-based strategies such as pancreatic islet transplantation hold the promise to cure 
Type1 diabetes (T1D) and advanced type 2 diabetes (T2D). However, this approach is 
severely limited by shortage of donor organs and the need of life-long 
immunosuppression. Stem-cell research might overcome this problem by generation of 
transplantable insulin-producing cells or regeneration of mature beta-cells. Search for in 
vitro differentiation of embryonic and adult stem cells into insulin phenotypes led to 
promising results.  
Adult mesenchymal stem cells (MSC) obtained from the bone marrow (hBM-MSC) 
represent an attractive potential source for beta-cell replacement since they are 
abundantly available and low immunogenic. Possible pancreatic progenitor/stem cells 
isolated from the ducts, acini and islet of Langerhans have been described to 
differentiate into insulin producing phenotypes. Particularly, islet derived cells, 
commonly designated islet derived progenitor cells (IPC) have been under intensive 
investigation regarding their epithelial or mesenchymal origin, stem cell character and 
capacity to replace beta cells in T1D.  
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Objectives 
In this study we intended to establish a reliable and reproducible model of human 
mesenchymal stem cells in order to evaluate the potential of hBM-MSC to be directed 
into insulin-producing cells and to overcome the donor variability and heterogeneity of 
primary MSC. 
In a second approach, it was our goal to determine the plasticity and molecular signature 
of primary hIPC, compare them to hBM-MSC and to evaluate their potential for 
replacement or regeneration of beta-cells. 
Methods 
I. In vitro differentiation of hMSC-TERTtowards insulin producing cells 
k) Evaluation of the expression of two stem/progenitor markers NESTIN e C-
MET/HGFR in the telomerase immortalized human mesenchymal stem cell line 
obtained from the bone marrow of a healthy young male adult (hMSC-TERT), 
by means of RT-PCR, flow-cytometry and immunocytochemistry.  
l) Culture of hMSC-TERT in specific endocrine promoting conditions for 9 days. 
After this period, expression of pancreatic endocrine gene markers were 
analysed by means of RT-PCR. 
m) Stable transfection of hMSC-TERT with two key regulatory genes of pancreatic 
endocrine maturation and function hNGN3 and/or hPDX1 giving rise to the 
generation of three new cell lines (hMSC-TERT-NGN3, hMSC-TERT-PDX1 
and hMSC-TERT-NGN3/PDX1). Islet gene markers expression including 
PAX4, PAX6, NEUROD1, PDX1, GLUT2, GCK and INSULIN) were analysed 
by RT-PCR. Insulin and C-peptide protein synthesis were detected by western 
blotting and immunocytochemistry.  
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n) Subsequently, functional analysis of new generated cell lines was performed 
using promoter gene activity assays, namely SEAP and Luciferase reporter gene 
assays. Insulin content and secretion were evaluated by an ELISA. 
II. Comparison of the functional signatures of primary hIPC and hBM-MSC 
o) Detection of hematopoietic (CD14, CD34, CD45) and mesenchymal (CD29, 
CD44, CD54, CD73, CD90 e CD105) surface antigen markers in primary hIPC 
(n=3) and hBM-MSC (n=5) was perfomed by flow-cytometry (FACS).  
p) hIPC and hBM-MSC were expanded and subjected to osteogenic, chondrogenic 
and adipogenic differentiation media according to standardized protocols. On 
the other hand, hIPC and hBM-MSC were cultured under endocrine 
differentiation conditions for 5 days.  
q) Mesenchymal gene markers (FNT, THY1, SNAI2, P4HA1, MMP2 e VIM ) and 
pancreatic endocrine differentiation markers (PAX4, PAX6, NGN3, NEUROD1, 
PDX1, GLUT2, GCK e INSULINA) were analysed by RT-PCR. Insulin and 
vimentin protein synthesis were demonstrated by fluorescence 
immunocytochemistry.  
r) Genome-wide gene expression profiling from hIPC (n=3) and hBM-MSC (n=5) 
was performed by microarray analysis of total RNA expression using Affymetrix 
Gene Chips HG-U133 Plus 2.0 . 
s) Transcriptional profiling within the two groups of samples was evaluated using 
the significance analysis of microarrays (SAM) approach. RT-PCR was used to 
partly confirm the microarray results.  
t) Expression of those target genes which where significantly differently expressed 
in hIPC and hBM-MSC was confirmed by means of real-time PCR (qPCR). 
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Results 
I. In vitro differentiation of hMSC-TERT towards insulin producing cells 
Specific culture conditions alone as well as hNGN3 and hPDX1 ectopic expression 
could induce pancreatic endocrine gene expression in hMSC-TERT including PAX4, 
PAX6, NEUROD1, INSULIN, GLUT2, GLUCAGON and SOMATOSTATIN.  
In hNGN3 overexpressing hMSC-TERT, endogenous NEUROD, PAX4 and PDX1 were 
activated similarly to the transcription factors cascade observed in pancreatogenesis. 
PDX1 was apparently sufficient to trigger endocrine differentiation in hMSC-TERT, 
suggesting an endodermal commitment in this mesenchymal population. 
Although overexpressing NGN3 and/or PDX1 hMSC-TERT were able to produce and 
secrete insulin, no glucose sensitivity was detected in either of the new-generated 
hMSC-TERT cell lines. 
II. Comparison of the functional signature of primary hIPC and hBM-MSC 
The results demonstrated that hIPC isolated from human pancreatic islets and hBM-
MSC obtained from human bone marrow display an overlapping immunophenotype. 
The significant expression of genes of the mesenchymal core and the expression of stem 
cell-related genes in both cell types, strongly suggests the MSC character othese cells. 
However, hIPC showed reduced differentiation potential towards mesenchymal lineages 
(bone, cartilage and fat) compared to hBM-MSC, which on the other hand exhibited a 
rudimentary endocrine differentiation capacity.  
In silico analysis (by means of informatics) of the obtained microarray data, 
demonstrated from a panel of important gene onthology groups that hIPC and hBM-
MSC are involved in very distinct biological processes. Moreover, detailed analysis of 
differentially expressed genes revealed marked differences in the expression pattern of 
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cadherin family genes, of key transcription factors for mesodermal and endodermal 
pathways like the HOX genes family and the SOX17 and ISL-1genes. 
In particular, in hIPC, a significant expression of genes known to be related to a cellular 
transitional state such as TCF21 and TGFb genes was detected. This was not found in 
hBM-MSC. 
Conclusions 
hMSC-TERT can be induced to activate pancreatic endocrine genes, therefore 
representing a reliable cell system to investigate the hMSC, as alternative source for β-
cell replacement or regeneration. However, higher endocrine maturation must be 
achieved, in order to obtain functional hMSC that might be suitable for the cell-based 
therapy of T1D and advanced T2D.  
Our results also suggest that hIPC are MSC, which maintain a specified phenotype 
related to the tissues where they reside. They display clear signs of epithelial-
mesenchymal transition (EMT) or MET, but are determinedly arrested in an 
intermediate state of differentiation. Further investigation is necessary to reveal if they 
are essential for islet regeneration and if they may complete their transitional state 
towards a mature endocrine phenotype.  
Our studies provided important knowledge to the molecular and functional signature of 
adult MSC populations derived from distinct tissues, giving new insight towards 
alternative cell sources to be used in cell-based therapies of T1D. 
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LISTA DE ABREVIATURAS / LIST OF ABBREVIATIONS3 
ABCC8  human Sur1 gene 
ABCG2  human ATP binding cassette group 2 gene 
AGEs   advanced glycation endproducts 
AGN    human aggrecan gene 
ALP   human alkaline phosphatase gene 
AMPK- AMP protein kinase or 5' adenosine monophosphate-activated protein 
   kinase 
APC   antigen presenting cells 
ATG   anti-thymocyte globulin 
bHLH   basic helix loop helix 
BMI   body mass index      
BMI1   human polycomb group repressor gene 1 
BM-MSC  bone marrow-derived mesenchymal stem cells 
BSA   bovine serum albumin 
BSP   human bone sialoprotein II gene 
CDH1   human E-cadherin gene 
CDH4   human retinal cadherin gene 
CDH6   human fetal kidney cadherin gene 
CDH11  human osteoblast cadherin gene 
CFA   complete Freund’s adjuvant 
                                                 
3 Reúne as abreviaturas em lingua portuguesa e inglesa, utilizadas no documento. 
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c-met/MET  protooncogene that encodes the protein MET also known as HGF  
   receptor  
COL II  human collagene type II gene 
COLX    human collagen type X gene 
COS7 cells  African Green Monkey SV40-transf'd kidney fibroblast cell liine. 
   They are useful in virus replication studies and transfection  
   studies. 
CSII   continuous subcutaneous insulin infusion 
Cy2   reactive water-soluble fluorescent dye of the cyanine dye family. 
   Cy2 is  excited maximally at 510 nm in the green region of the 
   visible spectrum 
Cy3   reactive water-soluble fluorescent dye of the cyanine dye family. 
   Cy3 is  excited maximally at 649 nm in the red region of the 
   visible spectrum  
Dapi   4' - 6- Diamidino-2-phenylindole (DAPI) forms fluorescent 
   complexes with natural double-stranded DNA (blue staining). 
   Useful tool in various cytochemical investigations.  
DCCT   diabetes control and complications trial 
DPP-4   dipeptyl peptidase 4 
DT1   Diabetes Mellitus tipo 1 
DT2   Diabetes Mellitus tipo 2 
EF1alpha  human housekeeping gene.  
EGF   epidermal growth factor  
EMT   epithelial-mesenchymal transition 
ES   embryonic stem cells 
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FACS   fluorescent activated cell sorting 
FasL R  Fas ligand receptor 
FBS   fetal bovine serum 
FC   fold change 
FCS   fetal calf serum 
FGF   fibroblast growth factor 
FGFR1  human fibroblast growth factor receptor 1 gene 
FGFR2  human fibroblast growth factor receptor 2 gene 
FITC   fluorescein isothiocyanate label 
FNT   human fibronectin gene 
FPG   fasting plasma glucose 
G6P   glucose 6 phosphate 
GAD65  glutamic-acid decarboxilase 65  antibody 
GCG   human glucagon gene  
GCK   human glucokinase gene 
GFP   green fluorescence protein  
GLP-1   human glucagon-like-peptide-1 gene 
GLUT2  human glucose transporter member 2 gene 
GO analysis  gene ontology analysis  
GOstat analyses statistical analysis of the gene ontology groups. 
HbA1c  glycated haemoglobin A1c 
hBM-MSC  human bone marrow-derived mesenchymal stem cells 
HES    human hairy enhancer of split gene 
HGF   hepatocyte growth factor 
hHCG   human chorionic gonadotrophin 
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hIPC   human pancreatic islet- progenitor cells  
HMGB1  human high mobility group box 1 gene 
hMSC-TERT  telomerase immortalized human mesenchymal stem cells 
HNF1β   human hepatic nuclear factor 1 homeobox B gene  (Mody 5) 
HNF1α   human hepatic nuclear factor 1 homeobox A gene ( Mody 3) 
HNF4α   human hepatic nuclear factor 4 alpha (Mody 1) 
hNGN3-pcDNA 3.1+ expression vector that includes the cytomegalovirus promoter-
   driven pcDNA 3.1+ sequence, the human NGN3 sequence and 
   the neomycin-resistance gene. 
HOXA   human homeobox gene family A  
hPDX1-pcDNA6/V5-His-A  
   expression vector that includes the cytomegalovirus promoter-
   driven  pcDNA6/V5-His-A sequence, the human PDX1 sequence 
   and the blasticidinb resistance gene. 
HPRT   human hypoxanthine phosphoribosyltransferase, used as  
   housekeeping gene 
HSC   hematopoietic stem cells 
HSP60   heatshock protein 60 
hUCB    human umbilical cord blood cells  
IA   insulin antibody 
IFNγ   interferon gamma 
IGF-1   insulin-growth factor 1 
IL-1b   interleukin -1 beta 
IL-1Ra  interleukin 1 receptor antagonist 
IL-8   interleukin -8 
LISTA DE ABREVIATURAS / LIST OF ABBREVIATIONS 
 
 
  
MSC for Cell-based Therapy of Type 1 Diabetes                                                                      31 
INS   human insulin gene 
INS-1E  rat pancreatic beta cell line  
ISL1   human islet 1 gene 
IPC   islet derived progenitor cells 
IPF1   human PDX-1 gene 
iPS   induced pluripotent stem cells 
KATP   ATP potassium channels 
KCJJ   human Kir6.2 protein gene 
Klf4   human Krueppel-like factor 4 gene 
KRB   Krebs-Ringer buffer 
LADA   latent autoimmune diabetes in the adult 
LDL   low density lipoproteins 
LPL   human lipoprotein lipase gene 
LUC   luciferase  
mAB   monoclonal antibody 
MAF   human v-maf musculoaponeurotic fibrosarcoma oncogene  
   homolog gene 
MAF   v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
MAFK   v-maf musculoaponeurotic fibrosarcoma oncogene homolog K  
MDI   multiple daily injections 
MEIS   human meis homeobox 1gene  
MEIS2  human meis homeobox 2 gene 
MET   mesenchymal epithelial transition 
MHCI   major histocompatibility complex 1 
MHCII  major histocompatibility complex II 
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MIDD   maternal inherited deafness and diabetes 
MMP2   human alpha I subunitmatrix metalloproteinase 2 gene  
MMP2  matrix metalloproteinase-2 
MMP9  matrix metalloproteinase-9 
MODY  maturity onset of diabetes of the young 
MSC   mesenchymal stem/stromal cells 
MtDNA  mitochondrial desoxiribonucleic acid  
NANOG  human homebox  transcription factor Nanog gene: 
   Encodes a transcription regulator involved in inner cell mass and 
   embryonic stem (ES) cells proliferation and self-renewal.  
   Imposes pluripotency  
NDM   neonatal diabetes mellitus 
NEUROD1  human neurogenic differentiation 1 gene: encodes pancreatic 
   endocrine differentiation transcription factor and regulates  
   expression of the insulin gene 
NGN3 or Neurog human neurogenine 3 transcription factor gene.  Member of the 
   subfamily of  basic- helix-loop-helix (bHLH) transcription 
   factors, involved in the determination of neural precursor cells in 
   the neuroectoderm and essential for  development of endocrine 
   pancreas.  
Ngn3   mouse neurogenine 3 transcription factor gene 
NOD mice  non obese diabetic mice 
NODAL  human Nodal gene, member of the TGF-beta superfamily.  
   Essential for mesoderm formation and axial patterning during 
   embryonic development.  
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OC   osteocalcin gene 
OCT   human Pou domain family genes, classically related with stem 
   cell character 
OCT1   POU domain class 2, transcription factor 1gene (POU2F1 gene) 
OCT3   human solute carrier family 22 member 3 (SLC22A3) gene 
OCT4   human POU domain, class 5, transcription factor 1 pseudogene 1 
   (Pou5F1 gene)  
OGTT   oral glucose tolerance test 
P4HA1  human prolyl 4-hydroxylase, alpha polypeptide I gene 
PAX4   human paired box 4 gene 
PAX6   human paired box 6 gene 
PBS   phosphate buffered saline 
PDX1   human pancreatic and duodenal homeobox 1 gene: encodes a 
   transcription factor involved in early pancreatic development, 
   beta cell maturation and glucose-dependent regulation of insulin 
   gene expression (Mody4)  
Pdx1   mouse pancreatic and duodenal homeobox 1 gene: 
PE   phycoerythrin label (stains red) 
PERV   porcine endogenous retrovirus 
PFA   paraformaldehyde 
PNDM  permanent neonatal diabetes mellitus 
POU   class 2 homeobox 1 gene  
PP   human pancreatic polypeptide gene 
PPARγ2  human peroxisome proliferator- activator receptor gama 2 gene 
PPARγ  peroxisome proliferator-activated receptors gama 
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pSEAP2   basic secreted alkaline phosphatase gene’s expression vector. 
PTD    protein transducer domain 
qPCR   real time protein chain reaction 
ROS   reactive oxygen species 
rPdx-1  recombinant pancreatic duodenal homeobox transcription factor 
   of the mouse 
RT-PCR  everse transcription polymerase chain reaction 
RUNX2  human runt-related transcription factor 2 gene 
RUNX3  human runt-related transcription factor 3 
SAM   significance analysis of microarrays 
SD   standard deviation 
SEAP   secreted alkaline phosphatase 
SNAI1   human snail1 gene 
SNAI2   human snail2 gene 
SOX17 SRY   (sex determining region Y)- box 17  gene 
SOX2   SRY (sex determining region Y)-box 2  
SST   human somatostatin gene 
SU   sulphonylureas  
T1D   Type 1 diabetes 
T2D   Type 2 diabetes 
T3D   Type 3 diabetes or diabetes due to specific mechanisms 
(neonatal,   monogenic, diabetes secondary to other diseases) 
TCF21 (Pod-1) human transcription factor 21 gene  
TEDDY  the environmental determinants of diabetes in the youth 
TF    transcription factor 
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TGFA   human transforming growth factor, alpha gene 
TGFB1  human transforming growth factor beta-1 gene. Encodes a  
   member of the transforming growth factor beta (TGFb) family of 
   cytokines 
TGFB2  human transforming growth factor, beta 2 gene 
TGFBR1  human transforming growth factor, beta receptor 1 gene 
THY1   human Thy-1 cell surface antigen gene (CD90 antigen) 
TNFα    tumor necrosis factor alpha 
Treg    Lymphocyte T regulatory cells 
tRNA   transfer ribonucleic acid. Small RNA molecule that transfers a 
   specific active  aminoacid to a growing polypeptide chain at the 
   ribosomal site of protein synthesis during translation. 
UC-MSC  umbilical cord-derived mesenchymal stem cells 
VDCC   voltage dependent calcium channel 
VIM   human vimentin gene 
Vit D   vitamin D 
VSEL   very small embryonic- like stem cells 
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A- INTRODUCTION 
1. DIABETES 
1.1. Definition 
Diabetes Mellitus is a metabolic disease of multiple etiologies characterized by chronic 
hyperglycaemia, with disturbances of the carbohydrate, fat and protein metabolism, due 
either to defects in insulin secretion, in insulin action or in both 1. Overt diabetes is 
defined by fasting plasma glucose (FPG) ≥ 126 mg/dl or 2 hours PG ≥ 200 mg/dl after 
oral glucose tolerance test (OGTT) 2. The two major forms, type 1 diabetes (T1D) and 
advanced type 2 diabetes (T2D) are characterized by a progressive loss of functional 
beta cell mass within the pancreatic islets, whereby resulting from distinct pathogenic 
mechanisms. T1D is a chronic autoimmune disease characterized by absolute insulin 
deficiency resulting from the progressive immune-mediated destruction of pancreatic 
islet beta cells. T2D results from a combination of both, impaired insulin action and 
deficient pancreatic beta cell function.  Both forms progress to long-term micro and 
macro vascular disease, which accounts for the high morbidity of diabetes. 
 
1.2. The silent epidemics 
The social and economical impact of diabetes is enormous. In all its forms, it affects 
nearly 200 million people worldwide 3. According to recent forecasts the global diabetes 
prevalence of 2,4% will explode to 4,8% within the next 30 years with the highest 
absolute rise to be expected in India. Demographic changes such as aging of the world 
population and urbanization in developing countries, which are related to changes in 
diet, reduced physical activity and stress are strongly associated to the rising numbers in 
diabetes across the world (Fig 1).  
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T1D represents 10% of all cases of diabetes, affecting mainly children and young adults 
3. It is thought to be triggered by as yet unidentified environmental factors in genetically 
susceptible individuals, the major genetic contribution coming from loci within the 
HLA complex, in particular HLA class II. The incidence of T1D has been increasing 
worldwide at an annual rate of approximately 3%. 4. According to the latest results from 
the EuroDiab (Epidemiology and Prevention of T1D) study group the greatest increase 
in incidence of T1D is observed among the youngest age groups (children <5 years old), 
which number is expected to double from 2005 to 2020 5. This means that with a 
younger age of onset, the prevalence of T1D < 15 years old in Europe will dramatically 
rise. The actual prediction is an increase of 94.000 cases in 2005 to 160.000 in 2020, 
with major health care implications. Interestingly, over the study period of 15 years, the 
rise in incidence was most significant in countries with typically low incidence rates 5. 
Such rapid increasing incidence of T1D within distinct ethnic groups cannot be 
explained by a rising transmission of the susceptibility genes. Instead, the declining 
proportion of newly diagnosed children with high-risk genotypes suggests that 
environmental pressures are now able to trigger T1D in genotypes that previously 
would not have developed the disease during childhood 4, 6. These epidemiologic 
observations stir up most important questions regarding the pathogenesis of diabetes. 
Which are the important environmental factors? Which mechanisms of action are 
involved: do they directly influence beta cell function or do they rouse epigenetic 
modifications that affect gene penetrance and genetic susceptibility? Currently, 
identification of possible environmental triggers of diabetes is a priority carried on by a 
study group of american and european diabetes centers, The Enviromental Determinants 
of Diabetes in the Youth (TEDDY ) 7. These include diet (vit D deficiency, early 
exposure to cow milk proteins and gluten, food composition), climate (exposure to ultra 
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violet radiations), low exposure to childhood infections, high birth weight, early weight 
gain and most important of all, childhood obesity 8, 9  
 
 
 
 
 
 
Fig 1: Prevalence of Diabetes Worldwide 
By the year 2025 the number of subjects with diabetes will have increased 
approximately 10-fold compared to figures observed in 1985. Adapted from Metabolic 
disease Group, Sanger Institute, UK 
 
Indeed, it is the increasing prevalence of obesity in all continents and ages, which is 
catching major attention 10, 11 (Fig 2). In the WHO European Region, about 30-80% of 
the adult population, is overweight - has a body mass index (BMI) over 25. Obesity 
(BMI over 30) affects up to a third of the adult population (Fig 3). Considered an 
important risk factor for diabetes, overweight people will steadily contribute for the 
growing public health burden of this disease 12.  
Also childhood obesity constitutes an acute health issue. About 20% of children are 
overweight, and a third of these are obese 13. In the last 10 years and due to the obesity 
epidemic, increasing number of children and adolescent are affected by abnormalities of 
glucose metabolism such as glucose intolerance, metabolic syndrome or T2D 14-16.  
Obesity induces beta cell apoptosis in predisposed individuals, raising the incidence of 
both, T1D and T2D. The underlying pathophysiologic mechanisms may be explained by 
the “accelerator hypothesis” according to which, the body mass index influences the 
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three key factors that variably accelerate beta cell apoptosis such as individual 
constitution, insulin resistance and autoimmunity. Consequently, weight gain induces 
insulin resistance, which leads to blood glucose disturbances. This is followed by 
glucose toxicity that results in beta cell apoptosis, inflammation and 
autoimmunogenecity in a genetic predisposed subset 9. 
 
 
 
 
                                          
 
 
 
 
 
 
Fig 2: Prevalence of Obesity worldwide 
An overweight individual is defined as having a Body Mass Index (BMI) ≥ 25. Obesity 
is defined as having a BMI ≥ 30 (weight ≥ 30/m2). Adapted (source) from World Health 
Organization. 
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Fig 3: Prevalence of excess body weight (including obesity) among 13-year-olds in 
 countries  of the WHO European Region, 2001/2002 
Shows the average prevalence of obesity and excess body weight in 13-year-olds in 35 
countries and sub-regions in the Region that participated in the HBSC 2001/2002 
survey. The prevalence of overweight and obese adolescents ranges from 3% to almost 
35% in 13-year-olds. Source: Health Behaviour in School-aged Children (HBSC) 
2001/2002 survey http://www.euro.who.int/Document/e82923.pdf 
 
1.3. Inflammation: a pathogenic link between Diabetes Mellitus and Obesity 
The concept that T1D is caused by a defect in insulin production and T2D is the result 
of defective insulin action does no longer hold true. Both these mechanisms that lead to 
impaired glucose control are pathogenic players in both types of Diabetes Mellitus. 
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In fact, increasing experimental data and epidemiological evidence show that insulin 
resistance is linked not only to T2D but also to T1D. Moreover, obesity, which is 
related to insulin resistance, is increasing worldwide hand in hand with T1D 17. 
This observation led to the formulation of the “accelerator hypothesis” which suggests 
that insulin resistance, together with genetic predisposition and autoimmunogenecity 
contribute as “accelerators” to the onset of T1D 9, 18. It is known that insulin resistance 
caused by obesity does not trigger or increases islets antibodies, but it influences beta 
cell dysfunction and the onset of T1D 19. 
On the other side, it is now well accepted that beta cell apoptosis is a common feature of 
T1D and T2D, being responsible for impaired insulin secretion in both diseases. Years 
of basic research have shown that finding one pathogenic model that integrates all the 
mechanisms involved is rather impossible since there are numerous intervenients and 
they seem to differ in T2 and T1D. 
While insulin resistance is a key player in the pathogenesis of T2D, it is not sufficient 
for T2D to occur since many obese patients with insulin resistance never develop 
diabetes. This means that, the genetic pattern related to beta cell function, survival and 
regeneration in each individual is crucial to determine the capacity of beta cells to 
survive in response to increased insulin demands 20, 21. Notably, none of the T2D genes 
is affected in T1D except for PPARγ, which is an inflammation-related gene 22, Qu, #329. 
Furthermore, recent data suggest that environmental factors acting early in life may 
modify HLA gene penetrance for T1D risk 23. The rising incidence and decreasing age 
at diagnosis of T1D is accounted for by the impact of environment on children with 
lower-risk HLA class II genes, who previously would not have developed T1D in 
childhood 23. Since T1D and T2D are genetically different diseases, it has been 
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suggested that enviromental factors involved in the genetic susceptibility of T1D might 
be different from those influencing T2D genetics 24.  
Although distinct genetic and environmental stimulus are triggering T1D and T2D, a 
common intracellular pathway in the beta cell has been identified with consequences on 
the regulation of apoptosis, insulin secretion and beta cell regeneration 24 (Fig 4). 
Preclinical data and molecular studies strongly indicate that the innate immune system 
is activated not only in T1D but also in T2D. This corresponds to a systemic 
inflammatory state characterized by increased circulating levels of acute-phase proteins, 
cytokines and chemokines. Ehses et al have demonstrated that a specific T2D milieu 
(high glucose and fat concentrations) induces the pancreatic islets to produce cytoquines 
(IL-1b) and chemokines (IL-8 from the classical chemiotactic factor CXC family) 25 
leading to a state of insulitis, similar to pre-T1D. These islet-derived cytokines (from 
beta, alpha and endothelial cells) and those produced by recruited immune cells can 
support adaptation and repair of islet cells, in a short time period. However continuous 
metabolic stress causes deleterious auto-inflammatory effects leading to beta cell 
apoptosis, impaired cell regeneration and insulin secretion (glucolipotoxicity)26.  
 
Similarly, obesity induces a state of lipotoxicity with increased circulating leptin, fat 
and glucose due to insulin resistance. Lipo and glucotoxicity cause increased levels of 
circulating cytokines and chemokines, activating the innate immune system and 
triggering a general systemic inflammatory state. In parallel, islet cells respond to this 
metabolic stress with an insulitis process 27, 28, which allows at first for beta cell 
adaptation in response to increased insulin demands. As in diabetes, continuos 
metabolic stress will activate intra-cellular signalling pathways, which interfere with the 
fine balance between apoptosis and regeneration of the beta cell. In T1D, the inherent 
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autoimmunogenic susceptibility leads to activation of the cellular (e.g.LT8 and LT4) 
and later on, the humoral immune system, which accelerates the loss of beta cell mass. 
As a result, rapid insulin deficiency and insulin dependency, arises. 
Therefore, the recognition that inflammation constitutes a common pathogenic link 
between T1D, T2D and obesity along with evidences from the experimental and 
epidemiological side, makes clear that 1) epidemic evolution of these diseases are not 
independent from each other. 2) understanding the role of islet-derived cytoquines and 
chemokines such as IL-1b and IL-8, opens the door to targeted clinical interventions 
aimed at remodeling islet inflammatory response in order to promote beta cell 
regeneration or to inhibit beta cell apoptosis.   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Inflammation: a pathogenic link between Diabetes Mellitus and Obesity 
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Environmental factors are determinant for the onset of T2D, T1D and obesity by 
influencing the specific genetic susceptibility for these diseases. In obesity, circulatory 
levels of fat and leptin increase and insulin resistance frequently occurs with 
disturbances of insulin action resulting in higher glucose concentration. Gluco and 
lipotoxicity induces an inflammatory response via the production of cytokines and 
chemokines by islet cells (mainly alpha, beta and endothelial cells) and by inflammatory 
cells of the innate immune system, which is also activated.  
In a first phase, inflammatory response of the islet exerts a protective and regenerative 
effect by stimulating beta cell function and replication, in order to re-establish metabolic 
control. However, sustained production of islet cytokines and chemokines, due to 
continuous metabolic stress, leads to deregulation of apoptosis pathways within the beta 
cell. Increased islet cytokines, in particular IL-1b and IFNγ induce apoptosis by 
activation of the MAPK/JNK pathways. In addition, IL-1b stimulates expression of Fas-
ligand receptor (FasL R) in the beta cell, which in cases of T1D genetic susceptibility, 
will sensitize beta cell to the T cell mediated apoptosis via the FasL. In T2D, glucose 
and possibly leptin will activate the same inflammatory response with disruption of 
common intracellular apoptotic pathways as in T1D. 
 
1.4. Other types of Diabetes 
Historically, diabetes classification has been based on the therapeutic approach towards 
correction of hyperglycaemia resuming Diabetes Mellitus to insulin-dependent and non 
insulin-dependent forms.   
In the last ten years, thanks to improved understanding of the disease, diabetes has been 
classified according to the pathogenesis of glucose intolerance in: 
1) Type 1 diabetes (T1D) (autoimmune) 
2) Type 2 diabetes (T2D) (non autoimmune) 
3) Type 3 diabetes (T3D) Diabetes due to specific mechanisms such as neonatal 
diabetes (NDM), maturity onset diabetes of the young (MODY) and diabetes associated 
to other diseases (secondary diabetes and syndromes) 
4) Gestational diabetes (insulin resistance during pregnancy) 1.  
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Nevertheless, based on clinical and laboratorial diagnostic and more recently on 
molecular genetic testing, other forms of diabetes have been identified. 
Latent autoimmune diabetes in the adult (LADA) or Type 1,5 diabetes, accounts for 5-
10% of diabetic older patients 29. Characterized by insulin resistance, low BMI, low C-
peptide and presence of anti-islet antibodies (especially anti glutamic acid 
descarboxilase 65 (GAD65), it is thought to be an autoimmune diabetes in adults with 
slowly progressive beta-cell failure 30.  
Monogenic diabetes is considered a rare type of diabetes mellitus (1-2%)  31 and is 
caused by one or more mutations in a single gene. Generally, it affects children in the 
first 6 months of life and includes permanent or transient neonatal diabetes. However, it 
may also arise in young adults < 25 years of age (former MODY). This form of diabetic 
disease should be suspected whenever T1D or T2D occurs with unusual clinical features 
or family history of diabetes 32.  
In monogenic diabetes, most mutations occur in beta-cell key regulatory genes, which 
result in beta-cell dysfunction, decreased pancreatic growth or even subtotal pancreatic 
agenesis.  Well-characterized mutations have been identified at genes encoding the 
glucose-transporter-2 (GLUT2), Glucokinase (GCK) and mitochondrial DNA (mtDNA), 
leading to reduced glucose sensing capacity. Mutations at the Kir6.2 and Sur1 protein 
genes (KCJJ and ABCC8 genes, respectively) of the membrane KATP channels typically 
affect insulin secretion mechanisms of the beta-cell. Insulin synthesis and packaging are 
disrupted in cases of pancreatic transcription factor’s mutations such as HNF1α 
(MODY3), HNF4α (MODY1), HNF1β (MODY5), NEUROD1 (MODY6), CEL 
(MODY7) and IPF1 (MODY4) (Fig 5). Among these, the most common is HNF1α 
(MODY3).  Depending on the number of mutations in one single gene, severity of the 
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clinical features varies from mild insulinopenia to pancreatic atrophy with permanent 
neonatal diabetes mellitus (PNDM/ MODY4).  
 
 
 
 
 
 
 
 
 
Fig 5: Pathogenesis of Monogenic Diabetes - pancreatic beta cell and the most frequent 
 genes  implicated in monogenic diabetes.  
In a physiological state, glucose enters the beta cell through passive diffusion which is 
facilitated by the glucose transporter 2 (GLUT2). It is phosphorylated into Glucose 6P 
(G6P) by glucokinase enzyme (GCK) and transformed into ATP via glycolysis or via 
Krebs cycle inside the mithocondria which involves mithocondrial DNA (mtDNA). 
ATP induces closure of the K+-ATP channels at the cellular membrane, preventing K+ 
efflux, subsequent membrane depolarization and opening of voltage dependent calcium 
channels (VDCC) with cellular Ca 2+ influx. Enhanced intracellular calcium levels, 
induces fusion of insulin vesicles with the membrane and stimulates insulin secretion. 
Sulphonylureas (SU), induce insulin secretion by closing the K+-ATP channels.    
Mutations in different genes lead to disruption of different functions in beta cell, 
including glucose sensing (red), insulin synthesis (green) and insulin secretion (blue) 
mechanisms. Parenthesis refers to the corresponding type of monogenic diabetes. 
Different mutations in the same gene may lead to several phenotypes of the same 
disease. NDM - neonatal diabetes mellitus; TNDM - transitory neonatal diabetes 
mellitus; PNDM - permanent neonatal diabetes mellitus; MIDD - maternal inherited 
diabetes and deafness. Adapted from Slingerland A.S. Rev.Endocr Metab Disord (2006) 
7:171-185 
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Monogenic diabetes associated with defects in the peripheral cell is very rare. It results 
from mutations in the insulin receptor gene, which leads to receptor degradation, no 
glucose-uptake and severe insulin resistance (Rabson-Mendenhall syndrome or 
Leprechaunism). In addition, insulin resistance may also be associated with familial 
lipodystrophies conditions.  
 
Molecular genetic diagnosis is essential in monogenic diabetes as it determines the 
treatment that a patient should receive 33. For instance, patients with HNF1alpha 
mutation are very sensitive to low dose sulphonylureas; glucokinase MODY patients 
need no treatment at all and patients with neonatal diabetes due to Kir6.2 mutation can 
discontinue insulin and be well controlled on high dose sulphonylurea tablets 34.  
 
Mitochondrial diabetes usually refers to the specific A-G mutation at the 3243 position 
from the tRNA (Leu (UUR)) gene in the mitochondrial DNA (mtDNA) 35, 36. It results 
in maternal-transmitted diabetes associated with sensorial deafness and short stature 
(MIDD), which manifests in young adult ages. Depending on the proportion of mtDNA 
affected, several phenotypes have been recognized. Meanwhile other mutations in 
mitochondrial or nuclear genes have been identified 37. 
Interestingly, recent studies strongly suggest that aging, age-related metabolic and 
degenerative disorders such like Alzheimer’s disease, cancer or T2D present 
mitochondrial dysfunction as a common underlying phenomenon 38. 
Mitochondrias are power factories with an independent genome (mtDNA) that generate 
ATP by oxidizing reduced equivalents from the citric acid cycle, via the respiratory 
chain. Several studies have shown that aging, oxidative stress and chronic 
hyperglycaemia promote mutated mitochondrial DNA (mtDNA) and damage of transfer 
RNA (tRNA) and mitochondrial proteins. In other words, mitochondria is considered 
one of the key regulators of longevity. Injured mitochondria promotes respiratory chain 
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deficiencies in several tissues like heart, skeletal muscle and brain, which in turn 
favours aging-related disorders 39 (Fig 6). Metabolic active tissues with high- energy 
demand, like the pancreas, are especially vulnerable to mitochondrial aging. Thus, in 
older individuals, aged/injured pancreatic mitochondria induce deficits of insulin 
secretion, leading to hyperglycaemia and direct acceleration of diabetic nephropathy in 
overt T2D 40 41.  
At present, an intense ongoing debate about the role of reactive oxygen species (ROS) 
and oxidative stress in the aging process exists. While there is a tendency to 
automatically link mitochondrial dysfunction to increased generation of ROS, the 
experimental support for this concept is weak. In fact, respiratory-chain-deficient mice 
with tissue-specific mtDNA depletion or massive increase of point mutations in mtDNA 
typically have aging-related phenotypes without evidence of increased oxidative stress 
42. Thus, mtDNA mutations causing respiratory chain dysfunction may accelerate aging 
by provoking bioenergy deficit in physiologically crucial cells, by decreasing the signal 
threshold for cell death, by inducing senescence in stem cells, or by some other 
mechanism.43. 
An increasing number of specific mutations associated to genetic susceptibility for 
diabetes have been identified due to recent advances on molecular genetic diagnosis 
22.These findings make us to consider that in the near future the etiological classification 
may give place to a genetic classification of Diabetes Mellitus. This would represent a 
milestone as far as the progress of treatment towards cure is concerned. 
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Fig 6: The role of mitochondrial dysfunction in diabetes and other age-related disorders 
 Well-characterized mitochondrial DNA (mtDNA) mutations (e.g. A3243G ) leads to 
inherited mitochondrial diabetes like the MIDD syndrome. Hyperglycaemia per si, 
aging and localized tissue oxidative stress have been related to injury of mitochondrial 
DNA, RNA and protein, which provoke respiratory chain deficiencies in physiological 
crucial cells. This favours chronic hyperglycaemia and acceleration of aging. Advanced 
glycation end products (AGEs) result from non-enzymatic protein glycosylation and 
contribute to reactive oxygen species (ROS) formation (superoxide, peroxide and free 
radicals) in the mitochondria. Both seem to play a key role in mitochondrial 
dysfunction, diabetic microvascular disease and other age-related disorders. Wether 
mitochondrial dysfunction leads to increased ROS production and therefore induces a 
self-perpetuating cycle of ROS/AGEs formation, is still not proven. 
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2. CURRENT MAIN THERAPEUTICAL STRATEGIES IN DIABETES 
2.1. Oral Antidiabetic Agents 
Treatment of diabetes mellitus has been focused on strategies to revert hyperglycemia 
upon low-carbohydrate diet, physical exercise and tight glycemic control, based on the 
knowledge of the deleterious effects of hyperglycemia in several tissues and organs. 
Thus, standard pharmaceutical agents for T2D include insulin secretagogues 
(sulphonylureas and meglitinides), insulin sensitizing drugs (biguanides and 
glitazones), incretin hormones (Glucagon-like-peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP)) analogues (exendine-4) and dipeptidyl 
peptidase 4 (DPP-4) inhibitors. Sulphonylureas and meglitinides are both K+ATP 
channel closers, which enhance insulin secretion from the beta cell. Oral biguanides 
(metformin) and glitazones (thiazolidinediones) are insulin sensitizers that stimulate the 
utilization of glucose mainly by the liver (metformin) and skeletal muscle and fat 
(glitazones). Incretins are intestinal hormones that exert multiple glucose-lowering 
effects, such as to stimulate glucose-dependent insulin secretion, inhibit glucagon 
secretion, delay gastric emptying, reduce food intake and also promote glucose 
utilization in peripheral tissues. 
Since circulatory incretin hormones, namely GLP-1 and GIP, are rapidly inactivated by 
the enzyme DPP-4, several long lasting analogues have been developed with similar 
glucose lowering effects. GLP-1 analogues have the disadvantage that they must be 
administered subcutaneously. DPP-4 inhibitors, by inhibiting the activity of DPP-4 
enzyme, indirectly increase endogenous GLP-1 concentration.   
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2.2. Insulin preparations 
Insulin replacement is essential for T1D. Also in later stages of T2D, beta cell mass is 
reduced by about 50%, and 20-30% of these patients require exogenous insulin to 
control hyperglycemia, when oral hypoglycemic agents fail 44.  
Most advanced insulin preparations are now available in the market. Well-tolerated 
synthetic human insulin compounds have long replaced former porcine and bovine 
derived insulin, which could cause allergic reactions (it was back in 1978 that 
Genentech started producing human synthetic insulin using recombinant DNA 
technology). Progress in genetic engineering techniques made available both, rapid-
acting insulin analogues (e.g. lispro and aspart insulin) and long acting insulins (e.g. 
glargine and detemir). These allow better glycemic control, flexible dietary regimens 
and most important, lead to a remarkable improvement on quality of life of T1D 
patients 45. 
In 1993, the Diabetes Control and Complications Trial (DCCT) demonstrated that 10 
years of intensive therapy of T1D significantly reduced the risk of development and 
progression of microvascular and neurological complications 46. Since then, efforts have 
been made to achieve near normal glycemia in T1D. The combination of continuous 
glucose monitoring with intensified insulin regimens using multiple daily injections 
(MDI) therapy could effectively improve metabolic control and reduce the incidence of 
long term micro and macrovascular complications in T1D 47 48, 49.  
Continuous subcutaneous insulin infusion (CSII) constitutes an alternative to MDI 
for those T1D and T2D patients under intensive insulin regimens. The secretor function 
of beta cells in response to physiological stimulus is complex and difficult to duplicate. 
Yet, CSII is the most physiological insulin delivery system currently available. With 
this method, it is possible to simulate the pattern of insulin secretion with a continuous 
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basal delivery and a superimposed mealtime “boluses”. The CSII depends on the 
utilization of insulin pumps, which allows more flexibility in life style, very small and 
precise insulin delivery and thus reduces the risk of severe hypoglycaemias and 
ketoacidosis, especially in childhood 50, 51.  Moreover, by improving long-term 
metabolic control (lower glycated haemoglobin A1c (HbA1c)) in adults and 
adolescents, CSII may lower the incidence of late complications in T1D 52. Recent 
meta-analysis of randomized controlled trials, comparing CSII and MDI in T1D and 
T2D patients show 1) lower HbA1c in adult T1D patients treated with CSII, but no 
differences in HbA1c of T2D patients treated with CSII compared to those on MDI.2) 
the effect of CSII on hypoglyceamias in T1D resulted in a sligth reduction, whereas in 
T2D, CSII and MDI had similar outcomes. The impact in patients with hypoglycemia 
unawareness or recurrent severe hypoglycemia is not known because of lack of data 53. 
Inhaled insulin represents a therapeutic alternative to the subcutaneous insulin 
injections. Two inhaled human insulin have been developed for the treatment of T1D 
and T2D. One is delivered as a dry power and the other in a liquid form, which provides 
more precise and smaller dosis of insulin. Both are used as pre-meals insulin bolus. 
Although, the lung tissues absorb them as fast as subcutaneous short acting insulin, the 
effect does not last long enough to maintain the basal needs 54. A meta analysis of 16 
open-label trials (4023 patients; age range, 18 to 80 years) have shown that inhaled 
insulins constitute an effective noninvasive option for premeal insulin administration, 
with slight less efficacy in glycemic control than subcutaneous regular insulin but 
increased patient acceptability 55. In children (6 to 11 years) with T1D, a three month 
randomised trial suggested that inhaled insulin compounds might be an effective and 
safe alternative to short acting analogues 56, particularly in those with resistance to 
subcutaneous insulin. Another open-label randomized controlled trial was recently 
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performed in oder to analyse two-year efficacy and safety of inhaled insulin compound 
in 385 T1D patients. Here, no differences between the SC and inhaled insulin group 
were found concerning insulin doses or hypoglycemic events. As in previous studies, 
HbA1c was significantly higher in the inhaled group (0.44%). Patients treated with 
inhaled insulin, developped larger (reversible) decline in diffusing capacity of the lung 
for carbon monoxide (CO). Greater weight gain was seen with SC insulin treatment 57. 
In summary, the key benefit of inhaled insulin compounds seems to be patient 
satisfaction and improved quality of life, which are significantly improved, due to 
reduce number of daily injections. However none of the inhaled insulin compounds 
could be implemented in the clinical use till now. Besides the respiratory side effects, 
the well-recognized lower bioavailabilities and hence higher doses of inhaled insulin 
required make it less cost-effective than injected insulin 58.  
 
2.3. Limitations of current therapies  
2.3.1. Secondary effects of insulin therapy 
Current therapeutic agents for the treatment of DM are considered to be safe. 
With the new generation of highly purified molecules and rDNA human insulins, severe 
immune reactions due to the use of exogenous insulin such as anaphilatic reactions are 
rarely seen and only few patients have mild hypersensitivity complications. 
Lipodistrophy (lipoatrophy and lipohypertrophy) at the injection sites became also rare 
due to the increasing use of rapidly absorbed analog insulins (e.g. insulin lispro, insulin 
aspart), which are also more anergic 59. Conversely, exceptional cases of lipoatrophy 
have been described in patients receiving rapid acting insulin analogs via CSII 60 or 
detemir 61. These findings suggest that local complications (abcess formation, 
INTRODUCTION – CURRENT THERAPEUTIC STRATEGIES 
  
MSC for Cell-based Therapy of Type 1 Diabetes                                                                      57 
lipodystrophies and mild immune reactions) remain a potential problem even with new 
insulin therapeutic technologies. 
 
Insulin resistance and unexplained hypoglycaemia episodes have been both attributed 
to anti-insulin antibody (IA) formation that occurs in almost every diabetic patient 
receiving exogenous insulin. Numerous studies suggested that insulin resistance, which 
manifests by increased insulin dose requirements, results from neutralization of the 
biological effect of circulating insulin by IA. Conversely, a correlation between IA 
levels and a prolonged effect of insulin causing hypoglycaemia was described in early 
reports. In fact, most studies published since 1980 have shown no evidence for a 
significant relationship between IA and average glycemia 62. No proof exists that 
humoral response to exogenous insulin affects insulin dose requirements, glycemic 
control or contributes to beta cell failure or long-term complications 63. Besides, the 
prevalence and titers of insulin antibodies in insulin-treated patients have markedly 
decreased, mainly as a consequence of the improvements in the purity of insulin 
preparations and because of the changes of species of insulin (human insulin).  
 
In recent years, intensive insulin treatment using MDI and specially CSII has been 
shown to improve life quality, metabolic control and reduce the risk of long term 
diabetes complications in both, T1D and advanced T2D 52. Nevertheless, in a recent 
prospective randomised study it was observed that in adult T2D patients with 
independent cardiovascular disease or additional cardiovascular risk factors, tight 
metabolic control was associated with unexpected deleterious effects. Indeed, intensive 
therapy to target normal HbA1c levels increased episodes of severe hypoglycaemia, 
induced significant weight gain and did not reduce cardiovascular complications. 
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Moreover, higher mortality rate was observed in these patients 64. These conflicting 
results reinforce the idea that no insulin regimen or delivery system can ensure 
physiologic glycaemic control in order to provide satisfactory prevention of diabetes 
complications.  
 
Although inhaled insulins may substitute subcutaneous short-acting insulin delivery in 
T2D patients, significant disadvantages dissuades physicians to advice this method. 
Based on observational studies, severe hypoglycemia is more frequent with inhaled 
insulin than with antidiabetic oral agents. Also, inhaled insulin causes mild to moderate 
nonprogressive dry cough and mild decreases in respiratory function in some 
individuals with T1 and T2D 55, 57. The latter is due the activation of IGF1 receptor in 
the lung, which leads to cell proliferation, enhanced connective tissue deposition and 
consequent reduction in gas exchange and lung compliance. In addition, inhaled insulin 
is unsuitable during intercurrent respiratory illness; it excludes children, smokers and 
individuals with significant pulmonary disease.  
  
2.3.2. Secondary effects of antidiabetic oral agents  
Current antidiabetic oral agents are widely used in T2D and some cases of monogenic 
diabetes, with high efficacy in a significant percentage of patients.  
The metabolic actions of metformin, occur via activation of AMP- activated protein 
kinase (AMPK) mainly in the liver, but also in the heart and peripheric tissues 65. 
AMPK enhances ATP-producing catabolic pathways, which reduces gluconeogenesis 
and increases glucose uptake in metabolic active cells including skeletal muscle 66, 67. 
Other beneficial effects such as lowering of serum low-density lipoproteins (LDL) and 
tryglycerides, stimulation of fibrinolysis and inhibition of oxidative stress have been 
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reported indicating thus, important additional cardiovascular benefits of this agent 68. 
The most common side effect of metformine is gastrointestinal intolerance resulting 
from the drug high concentration in upper intestinal tract leading to bowel irritation. 
More distally, metformin may alter bile salt absorption, which increases fluid retention 
and triggers loose stools and diarrhoea in some patients 69. These symptoms can be 
avoided by initial low doses and slow titration of the drug. Lactic acidosis is the most 
severe complication of metformin therapy. Its incidence, however, is very low and most 
cases occur with concomitant kidney or liver impaired functions 70. 
Glitazones, influence glucose and fat metabolism via binding to the nuclear peroxisome 
proliferator-activated receptors gama (PPARγ) at the heart, skeletal muscle and mainly 
at fat tissue. They facilitate glucose and lipid uptake, stimulate glucose oxidation, 
decrease free fatty acid level and ameliorate insulin resistance. PPARα and γ agonists 
have controversial pleiotropic effects namely on inflammation, vascular function, and 
vascular remodelling. While some studies have shown an increased risk for coronary 
heart disease with rosiglitazone, pioglitazone treatment appears to have a protective role 
against cardiovascular complications. At present, safety and clinical indication of PPAR 
agonists remain undetermined due to the incidence of heart disease in metabolic 
syndrome and T2D.  
Hypoglycaemia and weight gain are common side-effects of insulin secretagogues such 
as sulphonylureas and meglitinides. Moreover, recent studies have suggested that 
closure of the KATP channels by the sulphonylureas tolbutamide and glibenclamide may 
induce Ca2+ dependent beta cell failure and apoptosis in T2D 71, 72. In vivo clinical 
studies comparing insulin and glibenclamide in T2D patients corroborate these findings 
73.  Given the possible deleterious effect of some sulphonylureas, alternative insulin 
secretagoges are under investigation. Repaglinide and nateglinide sulphonylureas, of the 
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meglitinides group, are short acting closers of the KATP channels, which do not appear to 
induce beta cell apoptosis in their circulating concentrations 72. Curiously, and in 
contrast to sulphonylureas, KATP channel openers may protect the remaining beta cells 
from exhaustion by inhibiting their secretory function. Improvement of insulin secretion 
has been observed after short treatment with diazoxide in recent diagnosed T1D and 
T2D patients 74. 
Treatment with incretine mimetics like GLP-1 analogues and DPP-4 inhibitors provoke 
mild and transient gastrointestinal side effects. 
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3. STRATEGIES FOR THE FUTURE: “FROM TREATMENT TO CURE” 
Exogenous insulin therapy has been the single approach to treat T1D so far. Major 
improvements in insulin peptide activity, insulin delivery devices and glucose 
monitoring have been observed over the past years. Nevertheless, advances on the 
pathogenesis of diabetes, in its different forms, have raised much interest of 
investigators towards therapies targeting the cause of the disease.   
It is now well accepted that the cure for T1D and for many cases of T2D requires either 
regeneration or replacement of insulin producing cells. Thus, finding a functional 
substitute for the “missing beta-cell” or restoring regeneration capacities is a major goal 
in the field of diabetes research 75. On the other hand, modulation of the immunesystem 
and anti-inflammatory approaches in both T1D and T2D are crucial therapeutic research 
lines that may contribute to solve key pathogenic factors of the disease.  
    
3.1. Beta cell regeneration 
Adult endocrine pancreas is not a quiescent cell population. Like most tissues, islet cells 
are dynamically regulated by expansion and reduction mechanisms. There is enough 
evidence for beta-cell regeneration in animal models 76. In humans, increases in 
metabolic demand such as obesity, pregnancy and a first stage of insulin resistance, 
increases beta-cell mass 77. Conversely, subjects with diabetes (either T1D or T2D) 
show a decrease in beta-cell mass compared to weight-matched individuals 78. 
Although it is certain that beta-cell mass regeneration does occur, it has been largely 
discussed whether this happens through self-replication of mature beta-cells 79, through 
neogenesis of progenitor cells residing in the pancreas 80-83 or recruited from other 
tissues (bonafide differentiation) 84.  There have been studies suggesting that 
endogenous regeneration of beta-cell mass in rodents differs from that in humans. In 
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diabetic mice models, self- replication is the main process 79, whereas in humans, 
neogenesis from progenitor cells seems to be the predominant mechanism of 
compensation 80, 83, 85, 86. On the other hand, collected evidence over the past decade 
indicates that, in vivo, regeneration mechanisms of the adult endocrine pancreas vary 
according to the metabolic need signals and pancreatic injury levels (e.g. mild to severe 
destruction of the endocrine compartment). 87.  
 
Anyhow, loss of beta cell mass is the hallmark of most forms of diabetes. Thus, 
development of therapeutical strategies based on endogenous islet regeneration or ex 
vivo proliferation is an attractive option.  
Ex vivo expansion of human islets has been very difficult. After a period of time, insulin 
production and secretion capacity decline in these cells, probably caused by aging 
mechanisms and in vitro dedifferentiation of beta-cells. In recent years, however, in vivo 
and ex vivo experiments with human tissue using biomolecules have shown promising 
results. Beta-cellulin, which has been long recognised as a beta-cell mitogen, 88 
promotes beta cell regeneration in diabetic mice 89.  Activin A, another regulatory 
peptide of cell growth and differentiation, has been shown to induce endocrine 
differentiation in human foetal pancreatic cells 90. When administered in combination, 
beta-cellulin and activin A significantly increase islet regeneration and ameliorates 
glycemic control 91. 
Observations in the 90% pancreatectomized mice model provided first evidences for the 
major role of insulin growth factor -1 (IGF-1) in the regeneration or replication of beta-
cells in the injured pancreas 92. Other factors such as hepatocyte growth factor (HGF) 
and fibroblast growth factor (FGF), particularly when combined with serum free 
medium, have also been successful in expansion of cultivated pancreatic islets 93, 94. 
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 Insulinotropic agents, such as nicotinamid have been shown to prevent insulitis and to 
induce beta cell proliferation ex vivo as well as in vivo 95, 96. Also gastrin and epidermal 
growth factor (EGF) have been reported to enhance beta-cell mass expansion, both in 
vitro and in vivo 97. In culture, however, islet-treated cells show a short life-time, 
display progressive loss of insulin secretion and dedifferentiate. In vivo, combined 
therapy with gastrin and EGF partially restored beta cell mass and reversed 
hyperglycaemia, in non-obese diabetic (NOD) mice 97, 98. More recently, it was shown 
that combination therapy with gastrin and EGF in NOD diabetic mice transplanted with 
syngeneic islets inhibits autoimmune recurrence that normally occurs after 
transplantation and delays rejection of syngeneic grafts 99.  
Another group of intestinal peptides, the incretines, are already successful therapeutic 
agents in T2D. Indeed, glucagon -like peptide1 (GLP-1) and its analogue exendin-4 
(exenatide) are able to promote beta-cell mass expansion and inhibit apoptosis in vitro 
and in vivo 
100, 101.These peptides are also associated to a number of important 
physiological effects such as inhibition of glucagon release, delay of gastric emptying 
and reduction of appetite 102. Molecular studies have shown that Exendin-4 enhances 
beta-cell proliferation by stimulation of cell cycle regulators such as cycline-A2 via the 
cAMP dependent pathway. PDX1 transcription factor is essential for cAMP activation 
in the beta-cell.103, 104. Whether incretins exert protective and proliferative effect on 
beta-cells in a T1D context remains unclear. In animal models of T1D, there is much 
less evidence for a beta-cell preserving effect 105. 
Nevertheless, combination therapy with GLP-1 and gastrin restores normoglycemia in 
diabetic NOD mice by increasing the pancreatic beta-cell mass and reducing the 
autoimmune response.106 
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3.2. Immunomodulation in Type 1 Diabetes Mellitus 
In vivo restoration of beta-cell mass might prove beneficial for the reversal of 
hyperglycaemia. Yet, for this to be effective, the expanded beta-cells must be protected 
from ongoing autoimmune destruction by immunesuppression or even better, by 
immunomodulation approaches.  
First approaches towards suppression of T lymphocytes were performed using 
cyclosporine 107, 108. However, withdrawal of cyclosporine led to recurrence of the 
symptoms implying lifelong administration of the agent with the known risks of chronic 
immunosuppression.  
First studies, using monoclonal antibody against CD3 in NOD mice, have shown that 
short-term treatment could induce remission of established diabetes 109. Anti-CD3 exerts 
an immunomodulatory effect that involves the transforming growth factor beta (TGFβ)- 
producing  regulatory T cells (Treg). By stimulation of the Treg cells (CD4+, CD25+, 
foxp3+), antiCD3 IgG induces a state of immunotolerance and blocks the autoimmune 
destruction allowing islets regeneration and prevention of the disease110. In this context, 
a two-phase clinical trial was performed in recent-onset T1D patients using two 
humanized recombinant antiCD3 antibodies- OKT3 or ChAglyCD3, to evaluate the 
long-term metabolic effects of this immunoregulatory strategy in a randomised placebo-
control trial 111, 112. Results showed a higher C-peptide level and lower insulin dosis 
requirements in treated patients after 18 months of trial, suggesting that antiCD3 
therapy has the capacity to preserve existing beta-cells. While it confers a metabolic 
benefit no insulin independence was observed. Moreover, side effects such as flue-like 
symptoms as well as signs of clinical and laboratorial Epstein - Barr virus (EBV) 
infection were detected in all patients. Consistent with transient cytokine release 
following the first infusions, all symptoms disappeared 5-10 weeks after treatment. 
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Other immunomodulatory regimens to prevent destruction of beta-cell mass are 
currently on final clinical trial phases. Diapep277 is a 24 aminoacid peptide with 
similariries to the heat shock protein 60 (HSP60), which is a beta cell membrane auto-
antigen that contributes to the autoimmune reaction in T1D and LADA. Diapep277 has 
been suggested to exert immunomodulatory effects on diabetogenic T lymphocytes, 
therefore protecting beta cell from ongoing immune destruction and sustain insulin 
secretion without causing immunosupression 113. Results from several clinical trials 
revealed that treatment of adult T1D patients with Diapep277 significantly inhibits a 
decrease in stimulated C-peptide secretion (thus preserving beta cell function) without 
adverse effects. Also, it ameliorates glycemic control compared to placebo treated 
patients 114. However, in children at early onset of T1D, Diapep277 appears to have no 
beneficial effect in preserving beta-cell function or improving metabolic control 115. 
A recent approach, is the vaccination against the main beta-cell autoantigen, the 
glutamic acid decarboxylase 65 (GAD65), using adenoviral recombinant GAD65 
peptide. This therapy has been effective in reducing pancreatic insulitis and insulin 
requirements in newly diagnosed T1D mice 116. Results of a phase II clinical trial on 70 
recent diagnosed T1D patients (10-18 years old) treated with recombinant GAD peptide 
indicate, that two dosis of GAD autoantigen leads to preservation of residual beta cell 
mass by stimulation of an antigen-specific T cell population and induces long- lasting 
modulation of the general B cell memory 117.  
The beneficial effects on preservation of insulin secretion, common to all this 
immunomodulatory agents, are more notorious in patients that still have a high beta-cell 
reserve at start of the treatment (in the first 3 months after diabetes onset). 
Other most interesting agents with recognized immunomodulatory effects in T1D such 
as human chorionic gonadotrophic hormone (hHCG) 118, TGFβ1 119 and humanized 
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anti-thymocyte globulin (ATG) 120 are currently under investigation. Complete Freund's 
adjuvant (CFA), an antigen presenting cells (APC) activator, has shown to upregulate 
the immunosuppressive T regulatory (Treg) cells (CD4+, CD25+ and foxp3+), thus  
preventing the onset of diabetes in NOD mice 121 
 
3.3. Anti-inflammatory intervention in T1D and T2D 
Inflammation plays a major role in the pathogenesis of T1D. Interleukine-1 beta (IL-
1b), tumor necrosis factor alpha (TNFα) and interferon gamma(IFNγ)  are pro-
inflammatory cytokines involved in the course of insulitis that occurs during the 
autoimmune process of T1D. IL-1, in particular, modulates the interaction between the 
innate and adaptive immune systems. The apoptotic effects of IL-1 pathway on beta-cell 
and its role on T-lymphocyte regulation point to this molecule as beeing a potential 
interventional target in autoimmune diabetes mellitus 122.  Interestingly, Ehses and al. 
have shown that islets produce cytokines and chemokines in response to a T2D milieu 
of circulating nutrients 25. These findings suggest that opposite to previous knowledge, 
the pathophysiology of beta-cell apoptosis and islet failure observed in advanced T2D 
also entails an inflammatory process in response to the metabolic stress (in particular 
glucose toxicity) 24. In fact, beta-cells of T2D, when compared to those of non- diabetic 
patients have shown increased IL-1b concentration123. Moreover, gene array analysis of 
islet- RNA from T2D patients revealed enhanced IL-1b expression, induced by glucose 
and IL-1b auto-stimulation in beta-cells 124. Hence, modulation of intra-islet cytokines 
such as IL-1b may represent a promising therapeutic approach in T2D and T1D. Indeed, 
in a randomised double-blind placebo clinical trial with T2D patients, the administration 
of IL-1 receptor antagonist (IL-1Ra) significantly improved glycemic control, 
ameliorated insulin secretion and reduced inflammatory markers 125. Even though, only 
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44% of the treated patients responded to this therapy, which seems to be associated with 
lower levels of IL-1 Ra- predisposition in these individuals. In animal models of T1D, 
genetic or pharmacological blockage of IL-1 action also reduces disease incidence. 
Presently, clinical trials have been started to study the feasibility, safety and efficacy of 
IL-1 therapy in patients with T1D (AIDA study group)122.  
 
3.4. Cell-based therapy 
Cell therapies are based on the utilization of autologous or allogenic uncommitted 
multipotent stem/progenitor cells to replace or regenerate injured cells and tissues that 
account to the pathogenesis of multiple chronic and degenerative diseases. Basic and 
clinical research accomplished in the last years strongly suggest that stem/progenitor 
cells can be 1) induced ex vivo to proliferate and/or differentiate into specific cell 
lineages or 2) they can be in vivo stimulated to proliferate or to regenerate injured 
tissues. 3) Genetically modified stem/progenitor cells could also be used as a delivery 
system for therapeutic molecules into specific damaged tissues. On the other hand, 
development of therapies targeting cancer related stem- cells and its microenviroment 
represents a most promising approach in cancer research 126. Therefore, recent 
knowledge in stem cell biology has been providing enough evidence to the potential of 
“specific cells” to be used as tools or targets in regenerative medicine and cancer 
therapies. Parkinson disease, multiple sclerosis, acute myocardial infarction and bone 
fractures are some of the conditions where cell therapy approaches have been applied 
with positive outcome. Experimental settings for the cell-based therapy of neonatal 
hypoxia in animal models have also shown promising results. Moreover, efforts to 
identify, isolate and characterize tissue-resident progenitor cells in organs such as retina, 
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lung, intestinal tract, liver and pancreas, which are often affected by irreversible 
conditions, also represent major goals in stem cell biology research. 
  
3.5. Cell-based therapy in diabetes 
Cell-based therapy for T1D and advanced T2D, as in many other disorders has become 
a main research issue in diabetes field. There is not much doubt that functional insulin 
phenotypes are required in order to replace damaged beta-cells, so that insulin 
independence can be achieved in these patients. 
Endogenous insulin secretion could be restored for the first time, in 1966, after pancreas 
organ transplantation in a renal end-stage diabetic patient. But this recipient died 2 
months later from surgical complications. Since then important lines of investigation 
have been developed towards finding an alternative source of functional beta- like cells 
75 (Table 1).  
Islet Transplantation 
 Human pancreatic islet transplantation  
 Xenotransplantation (porcine origin) 
In vitro generation of human insulin producing cells 
 Generation of beta-cell lines (rodent and human) 
 Stem cells:  
  Embryonic stem cells 
  Adult stem / progenitor cells  
   Pancreatic (ductal, acinar, islet derived cells)  
   Extrapancreatic (liver, CNS, bone-marrow, fat) 
Induced pluripotent stem cells (iPS) 
In vivo reprogramming of beta cells 
 
Table 1: Potential sources for cell-based therapy in type 1 diabetes mellitus 
 Adapted from Limbert C. et al. Diabetes Res Clin Pract. 2008 Mar; 79(3): 389-99. Epub 
 2007 Sep 12.  
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3.5.1. Islet Transplantation  
Pancreatic islet transplantation represents an almost ideal approach to cure Diabetes 
Mellitus type 1. Data from the Edmonton protocol have convincingly demonstrated that 
in selected T1D patients (recurrent episodes of hypoglicemia, difficult metabolic 
control), human islet-transplantation (through the portal vein into the liver) leads to 
insulin independence and normalization of glycemic control 127. Compared to pancreas 
organ transplantation, human pancreatic islets engraftment is technically easier, has 
lower morbidity and permits storage of the islet graft in tissue culture or 
cryopreservation for banking 128. The low morbidity of the procedure and the potential 
for inducing tolerance to the grafted tissue define islet transplantation as a promising 
strategy for correcting diabetes in young patients, including children 129, 130. However, 
due to shortage of organs and life long immunosuppression this therapy can only be 
offered to a very limited number of patients. Besides, insulin independence lasts no 
longer than 2 years in 90% of transplanted subjects 131 (Fig 7). This fact might be due to 
ongoing autoimmune destruction or even to the aggressive immunosuppressive 
regimens, which inhibit beta-cell regeneration and prevent the normalization of glucose 
homeostasis 132. Typically, about 850.000 islets (11.000 islet equivalents/Kg or 2 human 
pancreas) are required for a single transplantation, which must be repeated to achieve 
insulin independence. 
As a result of these difficulties, intensive search for alternative sources of transplantable 
insulin producing cells has been undertaken in the last few years. 
Grafts of porcine islets represent a valuable source for obtaining beta-cells. However, 
the natural immunological inter-species barrier is of great disadvantage and several 
techniques have been developed to avoid xenotransplant immune rejection. Alginate-
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based microcapsules to involve the grafted islets have proven to confer immunoisolation 
and to allow for metabolic and nutrient changes that are essential for islet survival 133. 
Recently, better results have been achieved by inducing donor-specific tolerance in islet 
graft recipients.  Both, the administration of T-cell suppressive adjuvants, such as 
CTLA4 (CD152) Ig+ combined with anti-CD154 monoclonal antibody (mAB) or 
treatment with anti-adhesion molecule LFA-1 (CD11a) together with anti-CD154 
mABs, prolonged viability of microencapsulated porcine islets and restored 
normoglycemia for more than 1 year in transplanted diabetic mice 134, 135.  
Another approach is the utilization of islet grafts obtained from transgenic pigs, which 
do not express xenogenic surface antigens 136. 
Yet, pig islet xenotransplantation in humans is far from being clinically applicable due 
to risk of transmission of porcine pathogens to the human species. Particularly, the 
porcine endogenous retrovirus (PERV) zoonose, constitutes a major obstacle, since it is 
integrated in the pig genome and might be transmitted to the human cells in vitro, even 
if the islet’s source is a pathogen-free pig herd 137.  
 
 
 
 
 
 
 
Fig 7:  Five years follow-up of transplanted patients of the Edmonton’s protocol. 
Insulin independence requires repeated islet transplantation. Insulin independence 
significantly decreases after 24 months.  Adapted from Ryan et al., 2005, Diabetes. 
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3.5.2. Beta cell lines 
Rodent cell lines are extremely useful for studies on islet cell biology and on the 
transcriptional cascade of endocrine differentiation. Insulin secretory physiology has 
been characterised in tumor cell lines derived from primary culture of insulinomas 
developed in transgenic mice expressing the large T-antigen of SV40 in pancreatic beta-
cells. Nevertheless, due to their tumorigenic and allogenic characteristics, these animal 
cell lines cannot be used for clinical purposes.  
Therefore, great effort has been made in order to immortalize human beta cells 138, 139. 
This has proved to be a very difficult task because human beta-cells do not proliferate in 
vitro and dedifferentiate very rapidly in culture. Moreover, most of the human beta-cell 
lines generated tend to display an unstable phenotype, including loss of regulated 
insulin secretion in culture conditions. 
A reversibly immortalised human beta-cell line was established through introduction 
and subsequent removal of two immortalising genes, SV40T and hTERT 140. 
Transplantation of these cells into streptozotocin-induced diabetic mice resulted in 
apparent control of blood glucose levels for longer than 7 months. Although this human 
pancreatic beta-cell line seems to be functionally equivalent to primary cells, the use of 
highly genetically manipulated cells for clinical applications should be avoided, since 
their phenotypic features are not fully known and their potential for tumours formation 
is not excluded.  
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3.5.3. Stem cells 
Stem cells are uncommitted cells with self-renewal capacity (symmetric division), 
which under specific conditions are able to differentiate into mature somatic cells 
(asymmetric division) (Fig 8). 
 
 
 
 
 
 
 
Fig 8: The stem cell niche. 
Somatic cells residing in stem cell niches are main regulators of stem cell differentiation 
and proliferation. Published in Jakob F, Limbert C, et al. Current Rheumatology 
Reviews, 2008, 4, 148-154 
 
Embryonic stem cells (ES) are pluripotent diploid cells, derived from the inner mass of 
the mammalian blastocyst. They indefinitely proliferate in an undifferentiated state and 
can be induced to differentiate into cells of all three germ layers, ectoderme, mesoderme 
and endoderme, both in vivo and in vitro (Fig 9).   
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Fig 9: Schematic diagram showing the possible differentiation pathways of ES  
 Adapted from Mimeault, M. et al. Stem Cells 2006; 24:2319-2345 
Adult stem cells are present in most adult tissues. They reside in well-identified stem 
cell niches, which have been already recognized in several organs including intestinal, 
gonadal, hematopoietic tissues and hair follicle 141, 142 (Fig 10). Adult stem cells remain 
in its undifferentiated state until injury or unbalanced cell turnover occurs (proliferation 
versus apoptosis). Specific somatic cells residing within the niches play a key repressive 
or inductive regulatory role on stem cell fate 143 (Fig 10).  
Identification of different stem cell populations for clinical diagnosis, basic research and 
therapeutical strategies has been one of the most challenging tasks in stem cell research. 
Expression of classical stem-cell related markers such as CD45, CD34, CD133, nestin 
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and/or ABCG2 in adult stem cells as well as OCT-4, SSEA-4 and Nanog in embryonic 
stem cells (ES) and very small embryonic-like stem cells (VSEL) 144 have been of great 
help to isolate and characterize these cell populations. However, recent advances in 
molecular biology and flow-cytometry techniques, (with multi-parameter analysis of 
over 6-8 markers at the same time), strongly suggest that the same stem cell type may 
display different phenotypes and that different stem cell populations show an 
overlapping immunophenotype 145. One hypothesis to explain these findings is that 
organ-specific environment induces the different expression patterns, which points out 
to a commitment of recognized stem cells to the tissue where they reside. Thus, 
concepts such as “functional signature” and “positional memory” from the 
developmental biology may be applied to recognized stem cell populations 146. Another 
explanation might be that phenotypes differ because of different isolation and 
enrichment procedures. 
Several in vitro and in vivo experiments have suggested that adult stem cells from 
different origins could be induced to replace or regenerate injured tissues by 
overwhelming germ layer boundaries 147, 148. Yet, understanding the key molecular 
mechanisms that control stem cell fate in order to enable effective manipulation of cell 
populations is still required. In this context, DNA-encoded small molecule libraries, 
which have been useful in proofing biological systems in cancer research are now being 
adopted for stem cell-based therapies. Recent literature has described several natural 
and synthetic small molecules with the capacity to control stem cell self-renewal by 
targeting signal transduction pathways that affect DNA replication, cell differentiation 
and apoptosis. Examples of these compounds are retinoids, Activin-A, TGFbeta1, 
epidermal and hepatocyte growth factors 149. Undoubtedly, chemical approach to stem 
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cell biology and regenerative medicine seems to hold great promise as a tool for cell 
replacement therapies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10: The stem cell niches and their neibourghs  
Stem/progenitor cells reside in several adult tissues. Specific somatic cells take  
part of the stem cell niche environment. Source: Fuchs E. et al, Cell 2004, Vol. 116, 
769–7 
 
Embryonic stem cells (ES) and diabetes 
A remarkable step in diabetes cell-therapy research was achieved with the first 
experiments on mouse ES, demonstrating that such cells might constitute an unlimited 
supply of beta-cells 150. Subsequent studies have shown that, rodents 151, 152, monkey 153 
and humans ES 154, 155 could be induced to differentiate into insulin-producing cells.  
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Nevertheless, either with techniques of cellular genetic manipulation 150, 156 or with 
utilisation of specific culture conditions 157, 158 beta cell-like phenotypes did not exhibit 
significant insulin content or a physiological regulation of insulin secretion. Actually, 
insulin secretion in differentiated ES never exceeded 1,6% of the amount that a native 
beta-cell typically secretes.  
In other remarkable studies, mouse and human ES could be successfully differentiated 
into definitive endoderm (supposed precursors for pancreatic cells) 159, 160. Further 
induction towards beta-like cells showed a considerable quantity of insulin production 
but, so far, no glucose-responsive insulin secretion was observed in these phenotypes 
161-163.  
Importantly, ES investigation has been crucial to uncover developmental steps of the 
human pancreatic endocrine cell in vitro since up to this point almost all available data 
could only be obtained from animal models. One example is the recent knowledge that 
specific small molecules, such as FGF2, FGF4, retinoic acid and activin-A play a major 
role in the activation of major signalling pathways required for the differentiation of ES 
into pancreatic endoderme. Such discoveries have been of great help to further 
understand embryonic pancreas development and to improve the methodology for high-
efficiency beta-cell differentiation in vitro 164-166. 
Along with major ethical concerns regarding the harvesting of human ES, a crucial 
limitation of ES transplantation is the associated risk of teratomes and teratocarcinomes 
in humans. This risk has been delaying the breakthrough of ES for the development of 
new forms of regenerative medicine 167.  
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Adult stem cells within the pancreas  
Intensive efforts have been made to identify pancreatic stem/progenitor cells within the 
endocrine pancreas since its isolation and in vitro proliferation may represent an ideal 
solution for a cell-based replacement therapy in T1D. 
The first evidence for the existence of a pancreatic stem/progenitor cell came from 
studies in developing rodent embryos which demonstrated that exocrine and endocrine 
cells share a common origin of pancreatic endoderm 168. Data showing the potential of 
very early murine embryonic pancreatic Pdx1+, Cpa-1+ cells to differentiate into all cell 
lineages strongly indicates the presence of a multipotent pancreatic stem cell 169. Using 
a single cell cloning approach, Seaberg et al could identify rare multipotent precursor 
cells isolated from islets and ducts of adult mouse pancreas capable of producing 
neuronal populations of cells and  exocrine, endocrine and stellate pancreatic cells 170. 
Interestingly, embryonic and even adult pancreatic cells expressing the basic helix loop 
helix neurogenin 3 gene (NGN3/Neurog), can only give rise to cells of the endocrine 
pancreas 170, 171. Thus, Ngn3 is described as a key control factor for endocrine cell 
fate specification in uncommitted pancreatic progenitor cells, being proposed as a 
marker of islet precursor cells 172. Yet, the existence of a “true” pancreatic endocrine 
stem cell has been strongly questioned. Genetic lineage tracing studies have 
demonstrated that in steady states, pregnancy and animal models with 50-70% 
pancreatic injury, physiological beta-cell regenerative process corresponds to the 
replication of existing mature beta-cells, and not to differentiation of pancreatic 
progenitor cells 79, 132, 173. These data conflicts with several other studies that corroborate 
the existence of pancreatic precursor cells in pancreatic islets 76, 81, ducts 80 and acini 82, 
within the adult and fetal pancreas.170, 174, 175. More recently, using a unique pancreatic 
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injury model of duct ligation, Xu and co-authors have produced evidence for de novo 
generation of beta-cells from Ngn3+ pancreatic progenitor cells. Again, these cells 
could be found in islets, ducts, acini and epithelial enriched populations 86.  
Based on the previously described confirmed data, we can hypothezise that adult 
pancreatic regeneration occurs upon several rescue mechanisms depending on the 
physiological needs and injury degree. Apparently, a spectrum of pancreatic progenitors 
with several lineage potentials resides in the adult pancreas. Then, perhaps under 
steady-states, pregnancy, post natal growth and milder injuries, recruitment of existing 
mature beta cells may be sufficient to restore glucose homeostasis, whereas severe  beta 
cell destruction (90% pancreactomy or in duct ligation models) implicates 
differentiation of stem/progenitor cells residing in the pancreas87. 
The isolation of a distinct stem/progenitor cell within the endocrine pancreas depends 
on the identification of specific progenitor markers. Nestin, an intracytoplasmic 
filament protein present in neuro-precursor cells was suggested as candidate marker by 
several groups 176, 177. Nestin+ islet-derived cells display endocrine differentiating 
capacity. However, further investigation revealed its transient expression profile in very 
early phases of pancreatic development, which explains the recent observations that 
nestin+ cells located in the primitive pancreas generate both, the cells of endocrine and 
exocrine lineages 178, 179. In addition, nestin seems to be implicated in assimetrical 
division of stem cells 180 and so far it is considered a characteristic marker of multi-
lineage progenitor cells.  
Suzuki et al identified a cluster of surface antigen markers to obtain enriched 
populations of stem/ precursor cells from the adult and fetal mouse pancreas.These cells 
were positive for the hepatocyte growth factor (HGF) receptor gene (c-met/MET) and 
negative for the hematopoietic markers CD45, c-kit , FLk-1 and TER119 181. In humans, 
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however, the receptor c-Kit, which is known as an important hematopoietic precursor 
cell marker has been found to be dynamically expressed during foetal pancreas 
neogenesis. Its phosphorilation may be involved in early beta cell differentiation and 
survival, proposing c-kit as marker for human pancreatic progenitor cells 182. The 
conserved surface markers CD133 and CD49low were detected in mouse foetal 
pancreatic epithelium (at E13,5 weeks) and might also be relevant for the detection of 
stem/progenitor cells within the pancreas (Ngn3+ cells) 183. 
 
Extrapancreatic stem cells and diabetes 
Increasing knowledge concerning adult stem cells properties, namely self-renewal and 
high plasticity, has raised the interest for alternative cell sources, outside the pancreas, 
to be used in cellular-based strategies for Diabetes Mellitus. Indeed, extrapancreatic 
stem cells from liver 184, 185, central nervous system 186 and bone marrow 84, 187 have 
been described to differentiate into insulin-producing phenotypes.  Also umbilical cord-
derived mesenchymal stem cells (UC-MSC) have been found to differentiate in vivo 
into insulin-producing cells and to ameliorate glycemic control and glomerular 
hypertrophy when transplanted in T2D mice model 188 as well as in partial 
pancreactomized mice 189. MSC isolated from human umbilical cord Wharton’s jelly, 
which are easily available, present no risk of discomfort for the donor, and low risk of 
rejection also possess insulin producing ability in vitro and in vivo190.  Moreover, the 
observation of spontaneous expression of pancreatic endocrine transcription factors in 
human adipose tissue- derived MSCunder specific culture conditions, also suggests the 
endodermal switching capacity of these cells 191. In spite of this, none of these studies 
could generate true beta-cells with the capacity to secrete significant amounts of insulin 
in a glucose-sensing manner.  
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Bone marrow derived–mesenchymal stem cells (BM-MSC) 
The multilineage differentiation capacity of mesenchymal stromal cells (MSC) has been 
firstly described in the bone marrow (BM) 192.  In BM, there are at least two distinct 
populations of cells, both with high plasticity; hematopoietic stem cells (HSC) - the 
precursors of all mature blood cells 193, and mesenchymal stem cells (MSC). BM-MSC 
is a specific population within marrow stromal cells that has been shown to differentiate 
into mesodermal lineages, including fat 194, bone 195, cartilage 196, muscle 197 and also 
towards epithelial 198, neuroectodermal 199 and endodermal phenotypes 200.  Although no 
specific markers have been identified until now, isolation of BM-MSC is based on the 
selection of CD45-, CD14-, CD29+, CD90+, CD105+  and CD79+  bone marrow 
derived cells.  
Due to their migration and homing capacity, mesenchymal cells play a fundamental role 
in embryonic morphogenesis, tissue repair and regeneration 201. In BM-MSC, 
expression of several chemokine receptors, such as CXCR4 receptor for stem-cell factor 
1 strongly suggests these properties 202. Furthermore, extensive in vitro studies have 
suggested that BM-MSC exert immunosuppressive effects via modulation of both 
cellular and humoral immune pathways 203-206. In diabetes, one of the mechanisms by 
which MSC can prevent rejection of allogenic islet grafts is through the 
immunosuppressive activity of matrix metalloproteinase-2 and-9 (MMP2 and MMP9). 
Both metalloproteinases, seem to reduce surface expression of CD25 on responding T-
cells 207. 
 Due to their immunophenotype, BM-MSC are recognized as non-immunogenic cells 
(MHCI+, MHCII -, CD80-, CD86-, CD40-). This feature would allow for their 
allogenic transplantation with no need for immunosupression. On the other hand, the 
stromal supporting nature of MSC offers an additional advantage for maintenance of the 
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grafts or regeneration of injured tissues (Fig 11). Thus, MSC immunomodulatory and 
tissue supporting properties have raised the possibility of establishing allogeneic MSC 
banks for tissue regeneration. These facts are strongly reflected in the current 
exponential growth in stem cell research in the pharmaceutical and biotechnology 
communities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11: The bone marrow derived mesenchymal stem cell (BM-MSC) properties  
Bone marrow derived mesenchymal stem cells (BM-MSC) are defined by plastic 
adherence, expression of unspecific surface antigen markers such as CD90, CD105, 
CD79, CD29 and differentiation capacity into mesenchymal lineages including bone, 
cartilage, fat and muscle. Functional characterization of BM-MSC, have shown most 
important features, which renders these cells very attractive for cell-based therapies and 
in particular for beta-cell replacement in T1D. Published in Limbert C et al. Pediatr 
Diabetes. 2009 Sep; 10(6):413-9. Epub 2009 Jul 13. Review.  
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Reprogramming BM-MSC into insulin producing phenotypes 
In recent years, increasing body of evidence suggests that BM-MSC have the potential 
to differentiate in vitro into insulin producing cells in mouse 187, 208, 209 and human 210-212 
as well as to revert hyperglycemia in diabetic mice models 187, 209-211. First results have 
been achieved by ex vivo expansion of plastic adherent BM-MSC and prolonged 
endocrine culture conditions 187, 208, 209.  More recently, an endocrine beta-cell like 
phenotype with higher differentiation efficiency was obtained by forced expression of a 
pancreatic endocrine key factor, the pancreatic duodenal homeobox 1 gene (PDX1) in 
primary BM-MSC. 210, 211. , Also, epigenetic modification could induce differentiation 
of mice BM-MSC into insulin-producing cells, even in a glucose-sensing manner 213. 
However, efficacy of BM-MSC differentiation has been low and highly variable. This 
might be related to donor-specific variability, heterogeneity of MSC populations, and 
non-optimized differentiation protocols. Still, there might be unknown BM-MSC 
populations with suitable endocrine commitment to be found.  
 
iPS (induced pluripotent stem cells) 
Reprogramming adult somatic cells implicates induction or repression of key regulatory 
genes, which are able to switch cells from one lineage into another or to dedifferentiate 
a mature phenotype back to a more primitive state in order to obtain pluripotency. 
In pioneering experiments mouse and human fibroblasts have been successfully 
reprogrammed into ES-like stem cell lines. These induced pluripotent stem cells (iPS) 
were generated by retroviral or adenoviral transduction of 4 transcription factors 
(Oct3/4, Sox2, c-Myc and Klf4) that completely modified the epigenetic signature and 
phenotype of these cells 214, 215. Using the same techniques, murine liver and stomach 
cells have also been reprogrammed into iPS cells 216. iPS cells show characteristic 
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features of reprogrammed cells such as DNA demethylation, expression of endogenous 
pluripotency genes, give rise to teratomas, and contribute to multiple tissues, including 
the germ line, in chimeric mice.  
More recent reports show that Oct4 alone is sufficient to reprogram directly adult and 
fetal mouse neural stem cells to iPS cells 217. The therapeutic potential of iPS has been 
recently demonstrated by using reprogrammed fibroblasts for neural cell replacement in 
Parkinson’s disease animal model. In this study, it has been demonstrated that iPS cells 
can be efficiently differentiated into neural precursor cells, giving rise to neuronal and 
glial cell types in culture. Upon transplantation into the fetal mouse brain, the cells 
functionally integrate into the brain regions and ameliorate the symptoms 218. However, 
current methods for reprogramming require infection of somatic cells with multiple 
viral vectors, thereby excluding their use in transplantation medicine at this time. 
Anyhow, these are important achievements that raise hope in every field of regenerative 
medicine, including the ambitious target of producing patient-specific pluripotent stem 
cells. Noteworthy and extremely valuable in medical research, is the derivation of 
human iPS cell lines from patients with human genetic diseases to be used as a 
complement to animal models of disease 219.  
In the context of T1D, generation of functional beta-cell like phenotypes from skin 
fibroblast- derived iPS has already been achieved 220. In addition, Maher et al. were able 
to dedifferentiate adult somatic cells of two T1D patients, into iPS, which have the 
hallmarks of pluripotency and can be induced in vitro into insulin secreting cells 221.  
 
3.6. In vivo regeneration of the endocrine pancreas 
In a most challenging study, the combined injection of adenoviral transduced key 
pancreatic endocrine transcription factors, Pdx1, Maf-A and Ngn3 in diabetic mice was 
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capable of reprogramming mature exocrine cells into beta-cell like phenotypes222. In 
other recent report, recombinant Pdx1 protein (rPdx1) was directly injected via intra-
peritoneal to mice with streptozotocin induced diabetes. Pdx1 transcription factor 
possesses a protein transducer domain (PTD) which facilitates its entry into the cells. 
By a mechanism of cellular transduction, rPdx1 treatment promoted beta cell 
regeneration, differentiation of liver cells into insulin producing cells and restoration of 
normoglyceamia in diabetic mice. Avoiding potential side effects associated with the 
use of viral vectors, this innovative PTD-based protein therapy may offer a promising 
way to treat patients with diabetes 223. 
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4. FUTURE PERSPECTIVES 
Current therapeutic strategies of T1D are based on glyceamic control in order to 
minimize acute and late complications of diabetes. 
Decades of investigation provided fundamental knowledge regarding genetics, 
pathogenesis and pathophysiology of diabetes, guiding the development of new targeted 
therapies. 
Indeed, increasing amount of data lead us to expect that modern therapeutic approach of 
diabetes might soon be “curative” instead of symptomatic.  
Considering the previously described lines of investigation and respective results, it is 
quite clear that the cure for T1D and advanced T2D will require a combination of 
distinct strategies. Cell-based therapies may recover endogenous insulin production but 
modulation of the autoimmune disease behind T1D is essential to achieve an effective 
and long-lasting therapeutic intervention.  
Recovery of beta-cell function may be attained by stimulation of beta cell regeneration 
or by replacement of insulin-producing cells. It has been already demonstrated that 
endogenous beta cell-regeneration occurs, but the cellular and molecular pathways 
implicated in the proliferation of beta cell mass are still uncertain. Moreover, cells that 
can be differentiated into glucose-responsive insulin cell-types, without any risks after 
transplantation, have not yet been identified.  
Most encouraging approaches, based on the utilization of natural or synthetic small 
molecules to selectively regulate stem cell fate in vitro and in vivo are under 
investigation. Also, development of therapeutic compounds to stimulate endogenous 
cell regeneration or to induce mechanisms of homing and migration are important 
research strategies in the regenerative medicine field.   
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In Diabetes, although progress is encouraging, major gaps in our understanding of 
developmental biology of the pancreas and adult beta-cell dynamics remain to be 
bridged before a therapeutic application is made possible.  
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B- RESEARCH PROJECT 
1. OBJECTIVES 
The main goal of the investigation presented in this dissertation was to evaluate the 
potential of adult MSC to be used as alternative sources for the cell-based therapy of 
T1D and advanced T2D.  
In this context our objectives were: 
I. In vitro differentiation of hMSC-TERT towards insulin producing cells 
To determine the capacity of the human cell line hMSC-TERT, to be induced into the 
endocrine pathways and thereby beeing adopted as a suitable MSC cell model for 
further molecular endocrine diferentiation studies. 
II. Comparison of the functional signature of primary hIPC and hBM-MSC  
 To characterize the primary hIPC population and to compare its multilineage 
differentiation capacity with primary hBM-MSC, the gold standard of MSC. To 
determine the molecular signature and functions of hIPC compared to hBM-MSC at the 
gene expression level. To identify key target genes, useful for the isolation of MSC, 
holding an endocrine reprogramming potential. 
 
2. LINES OF INVESTIGATION/WORKSHEET  
I. In vitro differentiation of hMSC-TERT towards insulin producing cells  
This part of our project was entirely developed at the Laboratory for Metabolism, 
Endocrinology and Molecular Medicine of the Medizinische Klinik und Poliklinik II at 
the Universitätsklinikum Würzburg under the leadership and supervision of Professor 
Jochen Seufert and later on by Professor Franz Jakob. 
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This work has been submitted to Cytotherapy. 
Evaluation of hBM-MSC as alternative source for cell-based therapy of T1D 
To investigate the differentiation potential of adult MSC towards insulin producing 
cells, preliminary experiments were performed using primary human bone marrow-
derived cells. Isolation, proliferation and immuno-characterization using hematopoietic, 
endohelial and mesenchymal surface antigen markers were undertaken and results were 
compared to other cell populations such as human umbilical cord cells (hUCB), 
pancreatic islet- progenitor cells (hIPC) and hMSC-TERT cell line.  
In vitro differentiation of hMSC-TERT using specific culture conditions 
Difficulties to acquire human cells due to ethical concern, the limited proliferation rate 
related to cell senescence in primary cells and donors-related variability, led us to 
investigate the potential of the hMSC-TERT cell line, as a suitable cell system for 
endocrine differentiation studies in human MSC phenotypes. This cell line was gently 
offered by Professor Kassem from the University of Odense, South Danemark. 
Simonsen et al., 224 previously demonstrated the differentiation potential of hMSC-
TERT towards distinct mesodermal lineages, thus indicating its multipotent stem cell 
character. 
To test the pancreatic endocrine differentiation capacity of hMSC-TERT, in vitro 
differentiation was induced by means of specific culture conditions. The expression of 
islet endocrine genes was analysed. 
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In vitro reprogramming of hMSC-TERT by ectopic expression of pancreatic endocrine key 
regulatory genes 
Neurogenin3 (NGN3) and pancreatic duodenal homeobox 1 (PDX1) represent key 
developmental transcription factors in endocrine pancreatic organogenesis 225. In mice 
adult pancreas, Ngn3 + cells display progenitor capacity within the injured islet 86 and 
Pdx1 is also required for maturation and function of adult beta cells 225. To evaluate the 
effect of these genes on hMSC-TERT, we generated three new stable cell lines by 
transfection of hNGN3, hPDX1 or both genes in combination. In newly generated cell 
lines, transfected genes and their transcription factors (TFs) were assessed by RT-PCR 
and Western blotting, respectively. 
Disclosure of molecular mechanisms involved in pancreatic endocrine differentiation in 
reprogrammed hMSC-TERT 
Both, NGN3 and PDX1 play a major role in the pancreatic developmental transcription 
factor cascade 225. To assess the role of these transcription factors in the molecular 
mechanism of endocrine differentiation in our adult MSC system, we used two reporter 
genes assays. SEAP reporter gene assay was performed to disclose whether hNGN3 
and/or hPDX1 were able to activate human insulin promoter in hMSC-TERT. 
Luciferase assay was undertaken to determine whether hNGN3 directly activates the 
insulin promoter, or if its effect is mediated via the secondary induction of PDX1.  
For detection of endocrine genes and proteins in reprogrammed hMSC-TERT, we used 
RT-PCR and Immunofluorescence, respectively. 
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Functional evaluation of insulin secretion in reprogrammed hMSC-TERT 
A major goal in cell-based therapy of T1D is the generation of functional insulin-
producing cells that are able to replace injured beta-cells, by releasing insulin in 
physiological concentrations and in a glucose-sensing manner.  
We aimed to evaluate insulin expression and synthesis in newly generated hMSC-TERT 
- NGN3 /PDX1 using RT-PCR and Immunofluorescence. Insulin release and cellular 
content in response to glucose stimulation were assessed by an ELISA assay.  
II. Functional signature of hIPC compared to hBM-MSC 
The second part of our work was performed at the Laboratory for Musculoskeletal 
Research and Stem Cell Biology of the Orthopedic Department at the 
Universitätsklinikum Würzburg under the leadership and supervision of Professor Franz 
Jakob. The colaboration of this group, especially from Dr. Regina Ebert was extremely 
valuable concerning the large experience with the usage of primary human bone 
marrow derived MSC and well-established differentiation protocols in this lab.  
Microarrays for determination of genome-wide gene expression profiles were 
performed in colaboration with the BioChip-Laboratory, Universitätsklinikum at the 
University of Essen in Germany. This study was recently published in Stem Cell and 
Development 146 
The results obtained in the first part of the project put in evidence limitations regarding 
the insulin secretion and glucose sensing mechanism of differentiated hMSC-TERT. 
Although hMSC-TERT behave as adult stem cells towards mesenchymal lineages, they 
could not achieve complete endocrine reprogramming. These observations suggest that 
different MSC populations have different multipotent character and not all of them can 
go through the same differentiation pathways  
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Therefore, to achieve objective II, we seek the following lines of investigation: 
Characterization of hBM-MSC and hIPC  
In part II of this project, our first aim was to characterize and compare two primary 
MSC populations isolated from distinct organs: the mesodermal derived hBM-MSC and 
the multipotent cell population called human pancreatic Islet-derived Progenitor Cells 
(hIPC) that can be obtained from explanted human islets. For this purpose, we evaluated 
in both populations, the surface antigen pattern using flow cytometry, stem cell and 
mesenchymal gene expression markers using RT-PCR/ qPCR and gene expression 
profiling by significant analyses of microarrays. 
Multilineage differentiation potential of hIPC and hBM-MSC  
Both, IPC and BM-MSC have been under extensive investigation as alternative sources 
for beta-cell replacement in T1D. Initially recognized as islet progenitor cells, IPC have 
been described to develop into insulin secreting cells in vitro and to improve glucose 
homeostasis in vivo; very similar reports were obtained on human and rodent BM-MSC 
187, 210, 226-229
.Besides, IPC express mesenchymal marker genes 230 and have been 
described to undergo mesenchymal differentiation just like BM-MSC 226-229 
In the present study, to further analyse and compare the multipotent capacity of these 
two MSC populations, we induced both, hBM-MSC and hIPC to differentiate, in vitro, 
towards mesenchymal and pancreatic endocrine cell lineages. Differentiated phenotypes 
were then evaluated for mesenchymal and endocrine gene markers using RT-PCR. 
Specific mesenchymal and beta cell proteins were analysed in the obtained phenotypes 
by means of immunohistochemical approach. 
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Molecular signature and function of hBM-MSC and hIPC  
Although hIPC and hBM-MSC show common mesenchymal features, we found 
remarkable differences in their multipotent differentiation capacity. To identify the 
genes that are related to the distinct signatures and functional assignment of these two 
MSC populations, gene ontology clusters analysis and a candidate gene approach were 
performed in hIPC and hBM-MSC. 
Previous studies have shown contrasting results concerning the origin of hIPC: some 
have traced hIPC to be of mesenchymal origin 230, 231 and others suggest that hIPC 
correspond to endocrine cells under epithelial mesenchymal transition (EMT) due to in 
vitro cultivation 232. Therefore, to disclose the provenience of this cell population we 
performed a candidate gene approach in order to identify specific genes and pathways 
that might be determinant for the molecular signature of hIPC. 
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3. PERSONAL CONTRIBUTION INCLUDING ORIGINAL RESULTS 
I. In vitro differentiation of hMSC-TERT towards insulin producing cells 
I-1. Materials and Methods  
Unless otherwise specified, all chemicals were purchased from Invitrogen, Karlsruhe,, 
Germany. 
Cell Culture  
hMSC-TERT as obtained from Moustapha Kassem were generated  by retroviral 
transduction of bone marrow-derived MSC from a 33 year old healthy male donor and were 
routinely cultured as previously described 224. Human pancreatic islets were isolated 
according to a modified semi-automated digestion-filtration method 233, 234 at the Giessen 
Islet Isolation and Transplantation Centre (Germany) from human "research" pancreases 
obtained from brain-dead multi-organ donors after legal consent and approval from the local 
ethics committee,. Prior to experiments, islets were cultured for 1-5 days in RPMI 1640 (w/o 
glucose) supplemented with 5.6 mM glucose, 10% heat-inactivated fetal bovine serum 
(FBS), 2 mM L-glutamine,10 mM HEPES buffer, 1 mM sodium pyruvate, 100 units/ml 
penicillin and 100 µg/ml streptomycin. Endocrine differentiation of hMSC-TERT was 
induced by two approaches; (i) specific medium and (ii) ectopic overexpression of human 
NGN3 and/or human PDX1 proteins. For approach (i), 2.5 x 105 cells/ well were seeded in 6 
well plates and cultured for 8-9 days in a permissive endocrine differentiation medium. This 
consisted of serum-free DMEM/F12 containing 17.5 mM glucose, 10 mM nicotinamide, 2 
nM activin-A, 10 nM exendin-4, 100 pM hepatocyte growth factor (Sigma-Aldrich GmbH, 
Schnelldorf, Germany), 1% bovine serum albumin (BSA), 2 mM L-glutamine, 100 units/ml 
penicillin and 100 µg/ml streptomycin 95, 185 further on named as cocktail medium. For 
approach (ii) we generated transgenic hMSC-TERT cell lines with stable overexpression of 
NGN3 and/or PDX1 genes. After transfection, cells were kept in standard medium 
RESEARCH PROJECT – DIFFERENTIATION OF hMSC-TERT 
 
  
94 
complemented with selection antibiotics as described below. COS-7 cells were routinely 
cultured in DMEM with 10% FBS, 100 units/ ml penicillin and 100 µg/ml streptomycin. 
INS-1E cells were routinely cultured in RPMI 1640 containing 10% FBS, 1 mM sodium 
pyruvate, 2 mM L-glutamine,100 units/ml penicillin, 100 µg/ml streptomycin and 50 µM 
beta-mercapthoethanol. All cells were cultivated at 37°C in a humidified atmosphere of 5% 
CO2 and 95% air. 
 
Flow cytometry 
Cells were labelled by a human c-met-specific mouse antibody (1 µl/5 x 105 cells) (Biomol 
GmbH, Hamburg, Germany) and an FITC-conjugated goat antibody against mouse IgG1 
(Becton Dickinson GmbH, Heidelberg, Germany). Cells labelled by a FITC-conjugated 
isotype (1:100 dilution) (Becton Dickinson GmbH) served as negative control. Flow 
cytometry analysis (10,000 events) was performed using a FACSort apparatus and CellQuest 
software (Becton Dickinson GmbH) 
 
Transgenic cell lines 
The human NGN3 coding sequence 235was kindly provided by M. German and 
subcloned into a CMV promoter driven pcDNA3.1+ which includes a neomycin 
resistance gene (hNGN3-pcDNA 3.1+). The human PDX1 coding sequence was 
subcloned into CMV promoter driven pcDNA6/V5-His-A comprising a blasticidin 
resistance gene (hPDX1-pcDNA6/V5-His-A). For transfection, hMSC-TERT were 
seeded in 6-well plates (105 cells/well). At 50-70% confluence, cells were stably 
transfected with human NGN3, PDX1 or both genes, using the liposomal transfection 
reagent Metafectene (Biontex Laboratories GmbH, Martinsried/Planegg, Germany). 3 
µl Metafectene and 1 µg DNA of each linearized vector were added to the cells, 
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according to the manufacturer's instructions. Transfection efficiency as determined by 
GFP-expression from transfected plasmids in independent experiments was 60% (data 
not shown). After 5 days, selection of transfected cells has been initiated with standard 
medium containing 600 µg/ml neomycin (Calbiochem/Merck KGaA, Darmstadt, 
Germany) or 7.5 µg/ml blasticidin (selection medium). Appropriate antibiotic 
concentrations used for selection were determined (kill curves) prior to experiments.  
After 6 weeks in selection medium, surviving successfully transfected cells were 
cultured in standard medium with 10 x lower concentrations of antibiotics (maintenance 
medium). All transgenic hMSC-TERT clones from each generated line were set 
together and were designated hMSC-TERT-NGN3, hMSC-TERT-PDX1 and hMSC-
TERT-NGN3/PDX1, respectively. Experiments have been performed during the next 10 
passages. 
 
RT-PCR 
Total RNA was isolated by NucleoSpin RNA II Purification Kit (Macherey-Nagel 
GmbH & Co KG, Düren, Germany) which include DNAse digestion. Prior to PCR 
amplification, RNA samples were tested by house keeping gene PCR for presence of 
genomic DNA. Only RNA free of genomic DNA was reversely transcribed into cDNA 
by using Superscript III. Additionally, for further detection of residual genomic DNA 
co-amplification, specific “intron-spanning” primers were used.  PCR was performed 
using with the following conditions: 94 °C for 2 min; 94 ºC for 30 s, primer-specific 
annealing temperature for 30 s, 72 ºC for 30 s; 72 °C for 4 min (Primer sequences and 
conditions are listed in supplemental Tab 1). PCR products were separated by 1.5-2% 
agarose gel electrophoresis and visualised by ethidium-bromide staining. 
Western Blotting 
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Proteins were extracted by RIPA lysis buffer (Upstate/Biomol GmbH) containing 
Complete Mini EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany). 15 µg protein/ lane were separated by 10% SDS gel 
electrophoresis and transferred to PVDF membranes by semi-dry blotting using Towbin 
transfer buffer. Ectopic and endogenous protein expression of NGN3 and PDX1 in 
hMSC-TERT was detected using rabbit anti-human NGN3 (1:500) or goat anti-human 
PDX1 (1:500) antibodies (both Santa Cruz Biotechnology Inc., Heidelberg, Germany) 
and the horseradish peroxidase-conjugated secondary antibodies donkey anti-rabbit IgG 
and rabbit anti-goat IgG (Dako Deutschland GmbH, Hamburg, Germany). Bands were 
visualised by ECL Plus Western Blotting Detection Reagent (GE Healthcare Europe 
GmbH, Freiburg, Germany). COS-7 cells transiently transfected with hNGN3-
pcDNA3.1+ and/or hPDX1-pcDNA6/V5 His A served as positive control. Wild type 
hMSC-TERT and COS-7 cells were used as negative controls. 
 
Reporter Gene Analyses 
For secreted alkaline phosphatase (SEAP) reporter gene assay we used a -881 to +54 bp 
fragment of human insulin promoter subcloned into pSEAP2-Basic (-881hInsP-SEAP) 
236. SV40 promoter driven pSEAP-Control and promotorless pSEAP2-Basic 
(Clontech/Becton Dickinson GmbH) were used as positive and negative control, 
respectively. For luciferase reporter gene assays, a -912 to +55 bp fragment of the 
mouse (m)Pdx1 promoter was subcloned into pGL3basic (Promega GmbH, Mannheim, 
Germany) to obtain the -912mPdx1P-Luc plasmid. SV40 promoter driven pGL3-
Control and promoterless pGL3-Basic were used as positive and negative controls, 
respectively. All three generated cell lines and wild type hMSC-TERT were transiently 
transfected by the described vectors using Metafectene (Biontex) according to the 
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manusfacturer's instructions. Supernatants for assessment of secreted SEAP were 
obtained 36 h post transfection and measured using Great EscAPe SEAP 
Chemiluminescence Detection Kit (Clontech/Becton Dickinson GmbH). Values of 
alkaline phosphatase secretion were normalized to background activity of the 
promoterless SEAP2-Basic plasmid. Cell lysates for determination of luciferase activity 
were collected 48 h pos- transfection and measured using Luciferase Assay System 
(Promega GmbH). Values of luciferase activity were normalized to background activity 
of the promoterless pGL3-Basic plasmid. 
 
Fluorescent immunocytochemistry 
Mouse anti-human nestin (Chemicon, Schwalbach, Germany), guinea-pig anti-human 
insulin (1:500) (Dako Deutschland GmbH) and rabbit anti-human C-peptide (1:500) 
(Linco Research, Inc.) were used as primary antibodies. Anti-mouse IgG Cy3-
conjugated (1:1000), anti-guinea-pig IgG Cy2-conjugated (1:1000) and anti-rabbit IgG 
Cy3-conjugated (1:1000) (all Dianova GmbH, Hamburg, Germany) were used as 
secondary antibodies. Cells were plated in 4 well culture slides (Becton Dickinson 
GmbH), cultured for 24 h, fixed in 4% paraformaldehyde for 30 min and air-dried. For 
immunostaining, cells were permeabilized with 0.1%Triton X 100 for 5 min, blocked by 
5% species-specific normal serum for 30 min and incubated at room temperature with 
primary and appropriate secondary antibodies for 2 and 1 h, respectively. Cell nuclei 
were stained with DAPI. Slides were analysed by fluorescence microscopy (Carl Zeiss 
Jena GmbH, Jena, Germany) using Axiovision 4.4.1.0 software (Carl Zeiss Vision 
GmbH, Aarlen, Germany). Wild type hMSC-TERT served as negative and human islets 
as positive control. The number of insulin+ and C-peptide+ cells among the hMSC-
TERT-NGN3, hMSC-TERT-PDX1 and hMSC-TERT-NGN3/PDX1 was quantitatively 
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determined in 3 independent immunostaining experiments by counting stained cells in 4 
randomly taken microphotographs per experiment of each cell population using Adobe 
Photoshop CS8.0.1 (Adobe systems Inc.). 
 
Insulin release and content  
50.000 cells / well from each transgene cell line were seeded in 24 well plates and 
cultured for two days in maintenance medium. Prior to experiments cells were washed 
twice and pre-incubated for 1 h in Krebs-Ringer buffer (KRB) (Sigma-Aldrich GmbH) 
containing 0.1% BSA, followed by 1 h incubation in fresh KRB/0.1% BSA additionally 
supplemented with 0.5 mM 1-isobutyl-3-methylxanthine and 5 mM or 15 mM glucose. 
After collection of supernatants, cells were extracted in acetic acid containing 1% BSA 
and sonicated. Buffer and cell extracts were analysed using the human Insulin 
Ultrasensitive ELISA Kit (Mercodia, Upsala, Sweden) for specific detection of mature 
insulin. Insulin secretion into KRB and the remaining cellular insulin content were 
normalized to total cellular protein content of related samples. Wild type hMSC-TERT 
cells incubated in identical conditions were used as negative and rat INS-1E pancreatic 
beta cells as positive control. 
 
Statistical analysis  
All results are presented as mean values ± standard deviation (SD). Statistical analysis 
was performed using build in t test of GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, California, USA, www.graphpad.com). 
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I-2. Results 
 
hMSC-TERT express stem/progenitor cell markers 
Nestin and c-met (also known as HGF-R, hepatocyte growth factor receptor) gene 
expression was analysed to characterise the stem-cell predisposition of hMSC-TERT. 
MSC of the developing pancreas express the neural stem cell marker nestin 237, 238, 
which has also been described in both adult human and rat islets of Langerhans 177 as 
well as in bone marrow derived MSC populations 239. C-met is a surface marker of 
endodermal progenitor cells, such as hepatic 184, 240, 241 and pancreatic cells 181, and is 
also found in MSC populations 242. In the present study, both markers are detected in 
hMSC-TERT at mRNA levels by RT-PCR (Fig. 12A). Nestin (Fig. 12B) and c-met 
(Fig. 12C) protein expression was demonstrated by immunofluorescence and FACS 
analysis, respectively. C-met was observed in about 80% of hMSC-TERT. 
 
 
 
 
 
Fig. 12: Characterization of hMSC-TERT.  
(A): RT-PCR analysis of human nestin (NES) and c-met (MET) gene expression in 
hMSC-TERT and human islets. (B): Immunofluorescence costaining for 
intracytoplasmatic nestin protein (cy3 red) and nuclei (dapi blue) on hMSC-TERT 
(left). For negative control hMSC-TERT were stained with secondary antibody (cy3) 
and nuclei (dapi) (right). Scale bar, 20 µm. (C): Detection of human c-met surface 
antigen in hMSC-TERT using flow cytometry. 
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hMSC-TERT can be induced towards a pancreatic endocrine fate 
In a first approach, wild type hMSC-TERT were cultivated in serum-free cocktail 
medium to induce pancreatic endocrine differentiation by specific medium conditions. 
After 4-5 days in differentiation medium, cells become round-shaped, detach from the 
culture plate and form floating cell clusters (Fig. 13A right), whereas non-induced 
hMSC-TERT grow adherent and display a normal fibroblast-like shape (Fig. 13A left).  
While not specifically quantified, we observed that such cocktail-derived cell clusters 
exhibited reduced proliferation after 1 week and limited cell survival after 2 weeks in 
culture. These changes were not related to serum-free conditions since growth 
characteristics did not change after substitution of serum to BSA (serum-free) 
supplementation without addition of cocktail factors (data not shown). After 7-9 days, 
cocktail-treated hMSC-TERT clusters were analysed for specific endocrine pancreatic 
gene expression by RT-PCR and compared to untreated hMSC-TERT (Fig. 2B). 
Cocktail-induced cell clusters newly express the pancreatic transcription factors 
PAX4, ISL1, PDX1 and NEUROD1 as well as the pancreatic hormones 
somatostatin (SST), pancreatic polypeptide (PP), and insulin (INS). Furthermore, 
induction of glucose transporter 2 (GLUT2) expression was also observed, whereas 
NGN3 or glucagon (GCG) could not be newly detected upon cocktail culture 
conditions. Interestingly, in untreated hMSC-TERT, expression of the pancreatic alpha 
cell related transcription factor PAX6 was also detected. 
 
 
 
 
 
RESEARCH PROJECT – DIFFERENTIATION OF hMSC-TERT 
 
  
MSC for Cell-based Therapy of Type 1 Diabetes                                                                      101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: Effects of endocrine promoting culture conditions (cocktail) on hMSC-TERT.  
(A) Phase contrast images (10x magnification) of hMSC-TERT grown in standard 
medium (left), and hMSC-TERT cultivated in serum-free cocktail medium 
supplemented with 17 mM glucose and endocrine promoting factors (right). (B) 
Expression of pancreatic islet cell-related genes in induced hMSC-TERT-derived cell 
cluster compared to untreated  MSC-TERT (negative control) and human primary islets 
(positive control). PAX4, paired box 4; PAX6, paired box 6; ISL1, ISL LIM homeobox 
1; PDX1, pancreatic and duodenal homeobox 1; NGN3, neurogenin 3; GLUT2, glucose 
transporter 2; INS, insulin; SST, somatostatin; GCG, glucagon; NEUROD1, neurogenic 
differentiation 1; PP, pancreatic polypeptide; quality and amount of amplified cDNA 
was verified by EF1α house-keeping gene PCR. All data from Fig. 2 are representative 
(each n = 3). 
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Overexpression of human ectopic PDX1 and/or NGN3 in hMSC-TERT  
In a second approach, we aimed to investigate the potential of ectopic gene expression 
on differentiation of adult human MSC into endocrine pancreatic lineages. Therefore, 
two pancreatic endocrine key genes, human NGN3 and PDX1 alone or in combination, 
were stably transfected in hMSC-TERT. These newly generated transgenic cell lines 
were cultured in maintenance medium, without any influence by other endocrine-
permissive growth factors. Ectopic overexpression was stable within the investigated 
period of 10 population doublings and newly generated cell lines exhibited a 
proliferation rate comparable to wild type hMSC-TERT (data not shown). Stable 
overexpression of transgenes in hMSC-TERT cell lines was confirmed at the mRNA 
level by RT-PCR (Fig. 14A) and at the protein level by Western blotting (Fig. 14B). As 
a major notion, we observed PDX1 expression not only in transgenic hMSC-
TERT-PDX1 clones, but also in hMSC-TERT-NGN3. These results suggest that 
stable NGN3 overexpression in hMSC-TERT is sufficient to induce expression of 
endogenous PDX1 in these cells. On the other hand, NGN3 was not detected in 
hMSC-TERT-PDX1. As expected, double transgenic hMSC-TERT-NGN3/PDX1 cells 
express both respective genes. 
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Fig. 14: Expression of ectopic genes in transgenic hMSC-TERT 
(A) RT-PCR evaluation of NGN3 and PDX1 transcripts in hMSC-TERT overexpressing 
NGN3, PDX1 or both NGN3 and PDX1. (B) Detection of NGN3 and PDX1 protein 
synthesis by Western blot in transgenic cell lines. COS-7 transiently transfected with 
NGN3 or PDX1 served as positive and wild type hMSC-TERT and COS-7 as negative 
controls. All data from Fig. 3 are representative (each n = 3). 
 
Insulin and PDX1 promoter activity in hMSC-TERT transgenic cell lines 
To establish whether the human insulin gene was transcriptionally activated upon 
overexpression of NGN3 and/or PDX1 in hMSC-TERT cells, a human insulin promoter 
fragment (-881 to +54) driving expression of the SEAP reporter gene was transiently 
transfected into the new generated transgenic cells and hMSC-TERT wild type. 
Transfection efficiency as defined by control vector activity showed similar values of 
SEAP in the four transfected cell lines (data not shown). At 36 h after transfection, 
human insulin promoter activity, normalised to pSEAP2-Basic, was significantly 
induced in transgenic hMSC-TERTcell lines as compared to wild type controls 
(Fig. 15A). Besides, combined overexpression of NGN3/PDX1 provides no 
additional promoter activation over single stimulation of NGN3 or PDX1. 
We further investigated transcriptional PDX1 gene activity in transgenic hMSC-TERT 
cell lines by Luciferase reporter gene assay (Fig. 15B). Transfection efficiency was 
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similar in all cell lines as revealed by luciferase activity of the control vector (data not 
shown). Similar to insulin promoter activation, mPdx1 promoter activity normalised 
to pGL3-Basic was significantly induced in transgenic as compared to wild type 
hMSC-TERT thereby supporting the observation that ectopic NGN3 substantially 
induces endogenous PDX1 expression (Fig. 14). Activation of the mPdx1 promoter in 
NGN3 and PDX1 single transgenic hMSC-TERT was statistically similar. NGN3/PDX1 
double transgenic cells demonstrated a statistically significant increase versus NGN3 
but not versus PDX1 single transgenic cells. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15: Insulin and Pdx1 promoter activity in transgenic cell lines. 
 (A) Using a -881hInsP-SEAP reporter plasmid, insulin promoter activity was evaluated 
by SEAP reporter gene assay in hMSC-TERT-NGN3, hMSC-TERT-PDX1, hMSC-
TERT-NGN3/PDX1 and wild type hMSC-TERT (n = 6). Values of secreted alkaline 
phosphatase were normalized to the activity of the promoterless SEAP2-Basic plasmid 
(B) Evaluation of PDX1 promoter activity by Luciferase (LUC) gene reporter assay in 
the same cell lines using a -912mPdx1P-LUC reporter plasmid (n=4). Values of 
luciferase activity were normalized to background activity of the promoterless pGL3- 
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Basic plasmid. Columns in Fig. 4 represent means ± SD (*, versus wild type; #, versus 
NGN3; *, p < 0.05; **, p<0.01; *** / ###, p < 0.001). 
 
Expression of pancreatic endocrine genes in transgenic hMSC-TERT  
Expression of a panel of pancreatic islet-related and beta cell-specific genes was 
analysed by RT-PCR to evaluate the differentiation stage of hMSC-TERT following 
NGN3, PDX1 and NGN3/PDX1 overexpression (Fig. 16A). Induction of endocrine 
pancreatic transcription factor genes such as NEUROD1, PAX6, PAX4 and ISL1 
was observed. Notably, low levels of PAX6 expression observed in wild type hMSC-
TERT, were enhanced by overexpression of NGN3 and/or PDX1. Other beta cell-
specific genes such as GCK, GLUT2 and INS were also newly detected in all 
transgenic cell lines. Additionally, endocrine pancreatic gene expression such as GCG, 
PP and SST genes was induced in parallel. This may demonstrate the potential of 
NGN3 and PDX1 to trigger an overlap of alpha, PP and delta cell-specific 
reprogramming in hMSC-TERT. 
Synthesis and storage of insulin and c-peptide in transgenic hMSC-TERT 
To evaluate the maturation level of NGN3 and/or PDX1-induced endocrine phenotypes, 
synthesis of insulin protein was analysed by means of insulin and C-peptide fluorescent 
immunostaining in transgenic hMSC-TERT cell lines. (Fig. 16B and 16C) demonstrate 
insulin (green) and C-peptide (red) immunofluorescence in representative ocular fields 
of all 3 transgenic cell lines as compared to negative immunostaining in wild type 
hMSC-TERT. Human islets served as positive control. Quantification of cell numbers 
displaying C-peptide positive immunofluorescence demonstrated that about 35 to 
40% of transgenic hMSC-TERT were reprogrammed by overexpression of either 
NGN3, PDX1 or both (Fig. 5B).  
 
RESEARCH PROJECT – DIFFERENTIATION OF hMSC-TERT 
 
  
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16: Endocrine differentiation capacity of transgenic cell lines. 
(A) Activation of pancreatic islet-related gene markers in hMSC-TERT-NGN3, hMSC-
TERT-PDX1, hMSC-TERT-NGN3/PDX1, wild type hMSC-TERT (negative control) 
and human islets cells (positive control). GCK, glukokinase; for other abbreviations see 
legend of (Fig. 13). Representative gels (n = 3). (B) Immunostaining of Insulin (cy2, 
green) and nuclei (DAPI, blue) in the 3 generated hMSC-TERT cell lines compared to 
hMSC-TERT wild-type. Merge image shows that not all cells stain for insulin. Scale 
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bar, 20 µm. Representative pictures (n = 3). Number of C-peptide+ cells in wild type 
hMSC-TERT and differentiated transgenic cell lines overexpressing NGN3, PDX1or 
both NGN3 and PDX1. Columns in Fig. 5B represent mean ± SD (n = 3).  (C) Immune 
fluorescence of Insulin (cy2, green), C-peptide (cy3, red) and nuclei (DAPI, blue) in 
differentiated cells detected in hMSC-TERT-NGN3, hMSC-TERT-PDX1, and hMSC-
TERT-NGN3/PDX1 populations, and compared to hMSC-TERT wild-type. Scale bar, 
20 µm. Representative pictures (n = 3). 
 
Insulin release and content in transgenic hMSC-TERT 
We finally tested whether NGN3 and/or PDX1 transgenic hMSC-TERT cell lines were 
able to store (content) and secrete insulin. In wild type hMSC-TERT, no insulin was 
detected within the cells, nor was there any insulin secretion observed. In contrast, 
detectable insulin content and secretion was measured to a variable extend in all 
three transgenic cell lines (Fig. 17). While these results parallel the findings observed 
in the gene and protein expression studies (Figs. 13 and 16), insulin content and 
secretion was not enhanced by increasing glucose concentrations from 5 to 15 mM 
in all of the transgenic hMSC-TERT cell lines (Fig. 17). Moreover, INS-1E insulin 
secretion under identical conditions shows that insulin production in transgenic cell 
lines is below biological significance levels.  
 
 
 
 
 
 
Fig. 17:  Insulin response to glucose stimulation in transgenic cell lines  
hMSC-TERT-NGN3, hMSC-TERT-PDX1, and hMSC-TERT-NGN3/PDX1 were 
stimulated with 5 (grey bars) or 15 mM (black bars) glucose. Treated in identical 
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conditions, wild-type hMSC-TERT and INS-1E cells served as negative and positive 
controls respectively. (A) Secreted insulin was measured in supernatants and (B) insulin 
content was determined after protein extraction from investigated cells by ELISA. All 
columns in (Fig. 17) represent values normalised to related cellular protein content and 
were plotted as mean ± SD (n = 3). 
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II. Functional Signature of hIPC compared to hBM-MSC 
II-1. Materials and Methods  
 
Cell culture 
All media, fetal calf serum (FCS) and supplements were obtained from PAA (Linz, 
Austria). 
Human pancreatic islets were isolated at the Giessen Islet Isolation and Transplantation 
Centre (Germany) from human pancreases (n=3) obtained from brain-dead multi-organ 
donors after obtaining legal consent and approval from the local ethics committee, 
according to a modified semi-automated digestion-filtration method 233, 234. hIPC were 
obtained from freshly isolated human islets of 3 different donors as previously 
described 177 and expanded in RPMI 1640 medium supplemented with 10% fetal calf 
serum (FCS), 1 U/ml penicillin (P), 100 µg/ml streptomycin (S), 50 µM β-
mercaptoethanol (Sigma, Schnelldorf, Germany), 1 mM sodium pyruvate, 10 mM 
HEPES, 2 mM L-glutamine and 20 ng/ml recombinant human fibroblast growth factor 2 
(rHu bFGF), and 20 ng/ml epidermal growth factor (rHu EGF) (both Promocell, 
Heidelberg, Germany). Cells were plated onto 75 cm2 flasks (TPP, Trasadingen, 
Switzerland) and kept at 37ºC in a humidified atmosphere consisting of 5% CO2 and 
95% air. After 4-5 days the non-adherent cells were removed and the phenotypically 
similar adherent fibroblast-like cells were cultivated 4 weeks on monolayer prior to 
experiments. All experiments were performed at passage 3 or 4. 
hBM-MSC were harvested from bone marrow of femoral heads from 5 otherwise 
healthy patients (n=5) undergoing total hip arthroplasty. Informed consent was obtained 
from each patient and experiments were performed upon approval of the Local Ethics 
Committee. Whole bone marrow cells were initially seeded at a density of 6.6 x 105/cm2 
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to obtain hBM-MSC by plastic adherence. After 2 to 3 days of cultivation, non-adherent 
cells were removed and adherent cells were washed twice with phosphate buffered 
saline (PBS). Cells were cultivated and expanded in DMEM/Ham’s F-12 (1:1) medium 
supplemented with 10% fetal calf serum (FCS), 1 U/ml P, 100 µg/ml S, and 50 µg/ml 
L-ascorbic acid 2-phosphate. The culture medium (hBM-MSC medium) was changed 
every 3 to 4 days 243. All experiments were performed after 1 to 2 passages. 
 
Flow Cytometry 
hIPC (at passages 3, 4, 6, 12) and hBM-MSC (at passage 1-2) were detached with PBS- 
0,5% EDTA and re-suspended in PBS-1% bovine serum albumin (BSA) in a round 
bottom polystyrene tube and labeled with fluorescein isothiocyanate (FITC)- or 
phycoerythrin (PE)-conjugated monoclonal antibodies according to the manufacturer’s 
instructions. The antibodies used were: anti-human CD45-PE, CD14-PE, CD34-PE, 
CD-HLA-DR-FITC, CD13-PE, CD29-FITC, CD44-FITC, CD54-FITC, (ImmunoTools, 
Friesoythe, Germany), CD73-PE, CD90-PE, (BD Biosciences, Heidelberg, Germany) 
and CD105-FITC (Biotrend, Köln, Germany). Cells labeled with IgG1-FITC/IgG2a PE-
conjugated antibody (BD Biosciences) served as negative control. Prior to FACS 
analysis, cells were washed twice and resuspended in 100 µl of PBS-1% BSA solution. 
Flow cytometry analysis (10,000 events) was performed using a BD FACScan and 
CellQuest-software (both BD Biosciences, Heidelberg, Germany). 
 
Mesenchymal differentiation of hIPC and hBM-MSC  
For adipogenic and osteogenic differentiation, hIPC and hBM-MSC were seeded at a 
density of 3 x 104 cells per cm2 and incubated in differentiation medium for 14 days 
(adipogenic) and 28 days (osteogenic) as previously described 243. 
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Cells maintained in expansion medium served as negative controls.  
For chondrogenic differentiation, a cell culture system of high-density pellets was 
applied. To obtain chondrospheres, 2.5 x 105 cells were resuspended in chondrogenic 
differentiation medium, which contained 10 ng/ml TGFb1 (R&D Systems, Wiesbaden, 
Germany), centrifuged at 250 x g and cultured in tubes for up to 21 days as previously 
described 243. Pellets maintained in chondrogenic medium without addition of TGFb1 
served as negative controls.  
 
Pancreatic endocrine differentiation of hIPC and hBM-MSC  
For endocrine differentiation, hIPC and hBM-MSC were seeded in ultra low-attachment 
6-well plates (Corning, Schiphol-Rijk, Netherlands) and cultured for 4 days under 
specific endocrine conditions (cocktail medium), consisting of serum-free DMEM/F12 
containing 17.5 mM glucose, 10 mM nicotinamide, 2 nM activin-A, 10 nM exendin-4, 
100 pM hepatocyte growth factor (Sigma-Aldrich GmbH, Schnelldorf, Germany), 1% 
bovine serum albumin (BSA), 2 mM L-glutamine, 100 units/ml penicillin and 100 
µg/ml streptomycin 185, 191. Floating cluster-like formations were handpicked from 
cocktail medium and further analysis was performed. hIPC and hBM-MSC maintained 
in expansion medium served as negative controls. 
 
RNA isolation and RT-PCR 
Total RNA was obtained from differentiated and undifferentiated hIPC and hBM-MSC 
from 3 and 5 donors, respectively using the NucleoSpin RNA II kit (Macherey-Nagel, 
Düren, Germany, www.macherey-nagel.de) according to the manufacturer’s 
instructions. Reverse transcription was performed using BioScript reverse transcriptase 
and cDNA was amplified with BIOTAQ DNA Polymerase (both Bioline, Luckenwalde, 
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Germany) using the following parameters: 94°C, 2 min; primer-specific number of 
cycles: 94ºC, 30 s; primer-specific annealing temperature, 30 s; 72ºC, 30 s. The human 
specific primer pairs were designed to be located in different exons based on GeneBank 
sequences to distinguish the PCR products from possible genomic DNA contamination. 
PCR products were separated by 1.5-2% agarose gel electrophoresis, visualized by 
ethidium bromide staining and photographed by BioCapt gel documentation system 
(LTF, Wasserburg, Germany). Primer sequences, number of cycles and annealing 
temperatures are listed in Suppl. Tab. 2. 
 
Real-Time PCR (qPCR)  
cDNA samples were investigated for mRNA levels by qPCR using Light Cycler 2.0 
(Roche) and Q-PCR SYBR Geen Capillary Mastermix (Abgene/Thermo Fisher 
Scientific). Concentrations of mRNA levels in samples were calculated from external 
standard curves generated for each specific primer pair (dilution series: 1:1; 1:10; 1:100; 
1:1,000 and 1:10,000) by Light Cycler Software 3.5 (Roche). Every run with samples 
included an internal standard (1:1,000) from the same cDNA sample as used for 
generation of standard curves to normalise reaction efficiencies. Standard curves were 
generated from triplicates, while samples and internal standards were analysed in 
duplicates. Bench-tested qPCR primer pairs for human /HPRT/ (house-keeping gene) 
(Quantitect Hs_HPRT1), human /MAF/ (Quantitect Hs_MAF), human/ISL1/ 
(Quantitect Hs_ISL1), human/SOX17/ (Quantitect Hs_SOX17), human /HOXA2/ 
(Quantitect Hs_HOXA2), human /HOXA10/ (Quantitect Hs_HOXA10), human 
/TCF21/ (Quantitect Hs_TCF21), were obtained from commercial supplier (Qiagen). 
qPCR conditions (according to general Light Cycler instructions): 95°C for 10 min; 40 
cycles: 95°C for 15 s; 55°C (manufacturer's recommendation for all Quantitect primer) 
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for 10 s; 72°C for 20 s; followed by melting curve analyzation for specificity of qPCR 
products . 
 
Cytochemical analysis 
Adipogenic differentiation was examined by staining of intracytoplasmic lipid vesicles 
with Oil Red O. Cells were fixed in 4% paraformaldehyde (PFA) and incubated in 0.3% 
(wt/v) Oil Red O in 60% isopropanol (Merck, Darmstadt, Germany). Cell nuclei were 
counterstained with hematoxylin.  
Chondrogenic differentiation was visualized by staining of the sulphated proteoglycans 
with Alcian Blue. Chondrospheres were fixed in 4% PFA, dehydrated with graded 
ethanol series and embedded in paraffin and sectioned at a thickness of 4 µm. Sections 
were incubated in 1% (w/v) Alcian Blue pH 1.0 and counterstained with Nuclear Fast 
Red.  
Osteogenic differentiation was evaluated by staining for cytoplasmic alkaline 
phosphatase (ALP) (ALP Leucocyte Kit 86-C, Sigma Aldrich GmbH). For detection of 
calcium mineralization in the extracellular matrix, monolayers were fixed with 
methanol and stained with Alizarin Red S (1% w/v) (Chroma-Schmidt GmbH, Stuttgart, 
Germany). 
 
Immunofluorescence analysis 
Rabbit anti-human C-peptide (Linco Research, St. Charles, USA), guinea-pig anti-
human insulin and mouse anti-human vimentin (clone v9) (both Dako, Hamburg, 
Germany) were used as primary antibodies, anti-rabbit IgG-Cy3 at 1:500, 1:500 and 
1:2000 dilutions, respectively, in blocking buffer. Anti-rabbit IgG Cy3-conjugated and 
anti-guinea-pig IgG-Cy2 at 1:1000 dilution (both Dianova, Hamburg, Germany) and 
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anti-mouse IgG Alexa 555 (Invitrogen, Karlsruhe, Germany) at 1:2000 were used as 
secondary antibodies.  
hBM-MSC and hIPC , human pancreatic islet cryosections (8 µm) and free-floating cell 
clusters generated in cocktail medium were fixed in 4% PFA prior to staining, 
permeabilised with 0.1% Triton X 100, blocked in 5% serum and incubated at room 
temperature with primary and appropriate secondary antibodies for 60 min and 30 min, 
respectively. Cell nuclei were counterstained with DAPI. Slides were analyzed by 
fluorescence microscopy (Carl Zeiss, Jena, Germany) using Axiovision 4.6.1.0 software 
(Carl Zeiss Vision, Aalen, Germany) and laser scanning confocal microscopy (Zeiss 
LSM 510) with Zeiss LSM 510 software (Esslingen, Germany).  
 
Genome-wide gene expression profiling of hIPC and hBM-MSC populations 
Hybridization experiments were performed using Affymetrix Gene Chips HG-U133 
Plus 2.0 (54,000 probesets for 47,400 transcripts and 38,500 genes, High Wycombe, 
United Kingdom) and the corresponding kits according to the Affymetrix GeneChip 
Expression Analysis Technical Manual version 2 (www.affymetrix.com). Total RNA 
expression of 3 individual hIPC and 5 individual hBM-MSC preparations (at passage 3 
and 1, respectively) was detected with an Affymetrix Gene Chip Scanner 3000 and 
analyzed by Affymetrix GeneChip Operating Software 1.4. Transcriptional profiling 
within the two groups was evaluated using the significance analysis of microarrays 
(SAM) approach (http://www-stat.stanford.edu/~tibs/SAM/) 244.  
To assess differentially expressed genes between hIPC and hBM-MSC groups, pre-
defined conditions were established according to Affimetrix Gene Chip methodology. 
The number of “Present” calls for a given gene had to be greater than 50% in at least 
one of the groups and only those genes that displayed a signal log2 ratio of < -1 or > 1, 
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i.e. with a fold change (FC) lower than 0.5 and greater than 2, were taken into account. 
All other probesets were stated as “not differentially expressed”. In order to get reliable 
data, the q-value, i.e. false discovery rate had to be less than 10%. For heatmap creation, 
the program Spotfire DecisionSite for Functional Genomics 9.1.1 (Spotfire AB) 
(TIBCO Software Inc., Göteborg, Sweden) was used. 
To evaluate gene ontology clusters, further analysis was attained using GOstat 
(http://gostat.wehi.edu.au) 245 together with the Benjamini and Hochberg correction.  
 
II-2. Results 
 
Overlapping immunophenotypes of hIPC and hBM-MSC 
To evaluate the immunophenotype of adult hBM-MSC and hIPC, both cell populations 
were compared by means of surface antigen characterization using flow cytometry 
analysis. Both hBM-MSC and hIPC were negative for the hematopoietic markers CD14, 
CD34 and CD45, while both expressed the mesenchymal markers CD29, CD44, CD54, 
CD73, CD90 and CD105. According to recently established minimal criteria, these 
results reveal a MSC immunophenotype in both, hBM-MSC and hIPC 246 (Fig. 
18a). 
Similar mesenchymal gene marker expression in hIPC and hBM-MSC 
The expression of mesenchymal marker genes 247 was analyzed in both cell 
populations. Transcripts for fibronectin (FNT), Thy1 (THY1), snail2 (SNAI2), prolyl 4-
hydroxylase, alpha I subunit (P4HA1), matrix metalloproteinase 2 (MMP2) and 
vimentin (VIM) were detected in both hIPC and hBM-MSC. Although to a lesser 
extent, mRNA for the majority of investigated mesenchymal genes was also found 
in extracts of intact human pancreatic islets (hislets) (Fig. 18b). At the protein level, 
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the classical mesenchymal marker vimentin was present in the investigated cell 
populations as well as in cells within the human islets (Fig. 18d).  
Expression of genes related to stemness and development 
Development and stemness-associated gene transcripts were detected in both hIPC and 
hBM-MSC. There was similar expression in both populations of e.g. high mobility 
group box 1 (HMGB1), hairy enhancer of split (HES) and Pou domain (OCT) genes, 
polycomb group repressor gene 1 (BMI1) as well as ATP binding cassette group 2 
(ABCG2) transcripts. In contrast, Meis homeobox and some homeobox b (HOXb) 
family genes showed higher expression levels in hIPC (Fig 18c; Suppl. Tab. 1). As 
expected, embryonic stem cell markers or pluripotency markers like POU5F1, NANOG 
and Nodal were not expressed in either cell population (data not shown).  
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Fig. 18: Characterisation of hIPC and hBM-MSC. 
18a: Surface antigen characterisation of hIPC (left panel) and hBM-MSC (right panel) 
by FACS analysis of hematopoietic surface markers (upper panel) and mesenchymal 
surface markers (lower panel). Representative histograms, from at least 4 independent 
experiments on distinct passages (hIPC ≥ passage 3, hBM-MSC at passage 1 or 2). 
18b:RT-PCR analysis of mesenchymal marker expression in hislets, hIPC and BM-
MSC (n=3). EF1alpha was used as a housekeeping gene. Abbreviations: Fibronectin 
(FNT), matrix metalloproteinase 2 (MMP2), prolyl 4-hydroxylase, alpha I subunit 
(P4HA1), snail 2 (SNAI2), Thy1 (THY1), and vimentin (VIM) were amplified. 18c: 
Representative expression of stemness-related genes in hIPC and hBM-MSC from 3 
independent experiments. Abbreviations: ATP binding cassette group 2 (ABCG2), 
polycomb group repressor gene 1 (BMI1), hairy enhancer of split 1 (HES1), high 
mobility group box 1 (HMGB1), homeobox b 5 (HOXb5), meis homeobox 1 and 2 
(MEIS1, MEIS2), POU class 2 homeobox 1 (OCT1), and paired box 6 (PAX6b). 18d: 
Detection of vimentin (red) by fluorescence immunostaining in hislets, hIPC and hBM-
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MSC (n=3). Cell nuclei were stained with DAPI (lower panel). Cells stained with 
secondary antibody were used as negative control. Bar represents 20 µm.  
 
Mesenchymal differentiation potential of hIPC is reduced as compared to hBM-
MSC 
To compare mesenchymal differentiation capacities, adipogenic, chondrogenic and 
osteogenic differentiation were induced in hIPC and hBM-MSC at the same time. After 
adipogenic induction, transcripts for the adipogenic markers, lipoprotein lipase (LPL) 
and peroxisome proliferator-activated receptor (PPARγ2) were detected in both 
differentiated populations (Fig. 19a). However, oil droplet formation, a later marker 
of adipogenesis, was found to a lesser extent in hIPC than in hBM-MSC (Fig. 19b). 
After 3 weeks under chondrogenic conditions, transcripts for specific chondrogenic 
markers such as collagen type II (COL II) and Aggrecan (AGN) were detected in 
hBM-MSC whereas in hIPC only the hypertrophic cartilage marker collagen type 
X (COL X) was expressed (Fig. 19a). Alcian Blue staining indicated the presence of 
sulphated proteoglycans in both hIPC- and hBM-MSC-derived cell pellets (Fig. 19b). 
After 4 weeks in osteogenic conditions, both hIPC and hBM-MSC strongly stained for 
alkaline phosphatase (ALP). Similar expression patterns for the osteogenic markers 
osteocalcin (OC), ALP and bone sialoprotein II (BSP) was detected, the latter however, 
showed a much higher expression in hBM-MSC (Fig. 19a). The degree of in vitro 
mineralization of the extracellular matrix, which is an indicator of osteoblast 
maturation was clearly less pronounced in hIPC compared to hBM-MSC as shown 
by Alizarin Red staining (Fig. 19b). 
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Fig. 19: Mesenchymal differentiation potential of hIPC and hBM-MSC. 
19 a: Mesenchymal differentiation potential of hBM-MSC and hIPC monitored by RT-
PCR detection of adipogenic markers (upper panel), chondrogenic markers (middle 
panel) and osteogenic markers (lower panel). Undifferentiated hIPC were used as 
negative control (hIPC ctrl). EF1alpha was used as a housekeeping gene. Abbreviations: 
Adipogenic gene markers: lipoprotein lipase (LPL), peroxisome proliferator-activated 
receptor γ2 (PPARγ2); chondrogenic markers: collagen type II (COL II), collagen type 
X (COL X), aggrecan (AGN); osteogenic markers: osteocalcin (OC), alkaline 
phosphatase (ALP), bone sialoprotein II (BSP). 19 b: Mesenchymal differentiation 
potential of hIPC (upper panel) and hBM-MSC (middle panel) monitored by staining of 
oil droplets after adipogenic differentiation (first column), Alcian Blue staining after 
chondrogenic differentiation (second column), staining for alkaline phosphatase (third 
column) and mineralisation (forth column) after osteogenic differentiation. 
Undifferentiated hIPC (hIPC ctrl, lower panel) served as negative control. Bar 
represents 50 µm. Figure is representative of 3 independent experiments (hIPC at 
passage 3, hBM-MSC at passage 1 or 2). 
 
Endocrine differentiation in hIPC is more effective than in hBM-MSC 
Both cell types were kept in specific culture conditions to evaluate their endocrine 
differentiation potential. Within 4 days both cell types developed spherical cell clusters 
(Fig. 20a). Transcripts for the key transcription factor pancreatic-duodenal homeobox 1 
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(PDX1/Ipf1), as well as the early endocrine promoters of beta- and delta-cells PAX6 and 
PAX4 were detected in both hIPC and hBM-MSC after induction of endocrine 
differentiation (Fig. 20b). Neurogenin 3 (NGN3), a pancreatic endocrine progenitor cell 
marker, which is transiently expressed during differentiation into islet-like cells, was not 
detected in any of the treated populations (data not shown). On the other hand, 
expression of specific genes involved in beta-cell function such as the V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA), insulin (INS) and 
glucose transporter type 2 (GLUT2) were observed in differentiated hIPC but not in 
hBM-MSC. Detection of mRNA for glucagon (GCG), somatostatin (SST) and P 
polypeptide (PP) in hIPC suggests that some of these cells underwent 
differentiation steps towards various islet-cell phenotypes. Synthesis of insulin 
protein was detected by immunostaining of hIPC with anti-insulin and anti-c-
peptide antibodies (Fig. 20c), suggesting a high level of maturation in differentiated 
hIPC, which could not be observed in hBM-MSC (data not shown). 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Endocrine differentiation potential of hIPC and hBM-MSC 
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20 a: Cluster formation in hIPC (left) and hBM-MSC (right) after cultivation of cells in 
endocrine differentiation cocktail for 4 days. Bar represents 50 µm. 20 b: Endocrine 
differentiation of hIPC and hBM-MSC monitored by detection of endocrine markers. 
RNA from human islets served as positive control (islets), undifferentiated hIPC and 
hBM-MSC as negative controls. EF1alpha was used as a housekeeping gene. 
Abbreviations: insulin (INS), somatostatin (SST), glucagon (GCG), pancreatic 
polypeptide (PP), V-maf musculoaponeurotic fibrosarcoma oncogene homolog A 
(MAFA), pancreatic and duodenal homeobox 1 (PDX1), glucose transporter member 2 
(GLUT2), paired box 6 (PAX6). 20 c: Confocal imaging of endocrine differentiated 
hIPC immunostained for insulin (green) and c-peptide (red). Cell nuclei were stained 
with DAPI. Undifferentiated hIPC subjected to the same staining procedures served as 
negative control. Bar represents 20 µm. Figure is representative of 3 independent 
experiments (hIPC at passage ≥ 3, hBM-MSC at passage 1 or 2). 
 
Detection of epithelial and mesenchymal cells in human pancreatic islet 
To further evaluate the epithelial and mesenchymal cell populations residing in the 
islets of Langerhans, sections of isolated human pancreatic islets were analysed for the 
synthesis of insulin and vimentin by immunofluorescence. Vimentin-positive cells 
(red) were found among the insulin-stained cells (green), which shows the existence 
of a mesenchymal cell-population, within the pancreatic islet (Fig.21, left panel). 
The detection of vimentin and insulin co-labeled cells (yellowish) in adult human 
islets ex vivo strongly suggest that along with mature endocrine cells and 
mesenchymal cells, some others are found in an epithelial-mesenchymal or 
mesenchymal-epithelial state of transition (Fig. 21, right anel).  
RESEARCH PROJECT – FUNTIONAL SIGNATURE OF hIPC vs hBM-MSC 
  
  
122 
 
Fig 21: Detection of epithelial and mesenchymal cell markers in human pancreatic islets 
Confocal imaging of a human pancreatic islet, co-stained with insulin (green) and 
vimentin (red). Cell nuclei were stained with DAPI. The left panel shows 
insulin/vimentin positive cells (yellow, arrow) on a section of whole pancreatic islet 
(bar represents 20 µm). The right panel shows single cells from the same islets labelled 
for insulin and vimentin (arrow) (bar represents 5 µm) (n=3). 
 
SAM-based genome-wide expression profiling in hIPC and hBM-MSC 
 The comparative analysis of gene hybridization signals from microarrays derived from 
hBM-MSC and hIPC was carried out using Significance Analysis of Microarrays 
(SAM). 22484 probesets were equally expressed in hIPC and hBM-MSC, 1606 were 
significantly higher expressed in hIPC (FC>2), 1995, were significantly lower 
expressed in hIPC (FC<0.5) (Fig. 22a).  
 
Functional assignment of gene ontology clusters in hIPC and hBM-MSC 
To assign functional categories to the identified gene clusters, microarray gene 
expression profiles of hIPC and hBM-MSC were examined using gene ontology (GO) 
analysis. GOstat analysis in hIPC revealed a significant enrichment of functional 
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gene clusters related to “gland development”, “signal transduction” and “cell 
differentiation”. In contrast, in hBM-MSC, ontology groups like most remarkably 
“skeletal development”, but also “myogenesis” and “sensory organ development” 
were significantly overrepresented (Fig. 22b).  
 
Fig. 22: Genome-wide expression profiling in hIPC and hBM-MSC. 
22 a: Venn diagram of the number of probesets significantly upregulated (red) and 
downregulated (green) in hIPC (n=3) compared to hBM-MSC (n=5). Data were 
obtained by SAM (significance analysis of microarrays). 22 b: GOstat analyses of gene 
ontology clusters in hIPC (n=3) and hBM-MSC (n=5). Enriched onthology groups in 
hIPC (left bar) and in hBM-MSC (right bar) are displayed. 
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Candidate gene clusters in hIPC and hBM-MSC 
To identify relevant genes associated with mesenchymal or epithelial determination, 
cell-transition state and key organ morphogenesis, a candidate gene approach was used, 
based on the significantly differentially expressed genes in hIPC versus hBM-MSC 
which have been obtained by SAM. The expression pattern of key genes in both 
populations was compared on the basis of SAM data and verified by RT-PCR. Some of 
these genes were quantified by qPCR (Tab.1, Fig. 23a, b and c).  
E-cadherin (CDH1), the classical epithelial marker was negative in hIPC albeit 
slightly expressed in hBM-MSC, while vimentin was strongly present in both 
populations (see also Fig. 18). Retinal cadherin (CDH4) was equally present in both 
populations according to RT-PCR analysis, in this case discongruent to SAM data. Also 
fetal kidney cadherin (CDH6) and osteoblast cadherin (CDH11) were equally expressed 
in hIPC and hBM-MSC. All other cadherins were either not differentially expressed or 
absent in either population (Tab. 1). 
The expression pattern of E-cadherin repressor genes was very similar in hIPC and in 
hBM-MSC (Tab. 1) as shown by the expression of SNAI1 and SNAI2, TCF3 as well as 
LOXL2. In contrast, while TWIST1 (FC 0.31) and SIP1, the E-cadherin promoter 
silencer (FC 0.34) were lower in hIPC, higher expression was found for TWIST2 (mean 
FC 2.5), the high mobility group protein HMGA2 (mean FC 2.8) and hepatocyte growth 
factor (HGF) (mean FC 4.0). 
Finally, we looked for mesenchymal marker genes relevant in mesoderm specification 
and MSC differentiation versus those that are relevant for endocrine differentiation 
(Tab. 1 and Fig. 23a and c). hIPC displayed comparably low levels of fibroblast growth 
factor receptor 2 (FGFR2) (mean FC 0.06), which is active in MSC differentiation 
while mesenchyme-specific MAFK expression (FC 2.94) was relatively high. V-maf 
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musculoaponeurotic fibrosarcoma oncogene homolog (MAF/c-MAF), which is active in 
chondrocyte differentiation, was low (FC 0.04) in hIPC, as was its homolog MAFB 
(mean FC 0.17), which is largely expressed in developing endocrine pancreas and 
induces the glucagon promoter in adult alpha-cells. This indicates that hIPC on one 
hand display many mesenchymal features but their differentiation towards mature 
mesenchymal cells is hampered due to important signaling defects. TCF21 (Pod-1), a 
basic helix-loop-helix transcription factor, is highly expressed in hIPC only (Fig. 23c). 
It represses terminal lineage maturation in myoblasts and is critically important for e.g. 
kidney organogenesis, suggesting that hIPC may be prohibited from mesenchymal 
maturation 248. The expression pattern of members of the highly conserved homeobox 
gene family (HOX) is different in hIPC compared to hBM-MSC (Fig. 23b and c). 
HoxA2, HoxA3, HoxA4 and HoxA5 are significantly higher expressed in hIPC, while 
HoxA7, HoxA9, HoxA10 and HoxA13 are higher expressed in hBM-MSC. SRY sex 
determining box 17 (SOX17), a marker for definitive endoderm, was detected in hIPC 
but not in hBM-MSC (Fig. 23c) 
Components of the TGFb signaling pathway were in part differentially expressed in 
hIPC (Tab. 1). While the expression of TGFBR2 and 3 were similar, TGFBR1 
expression was lower (mean FC 0.37) in hIPC. TGFBR ligands were also differentially 
expressed. TGFA (FC 0.13) and TGFB2 (FC 0.26) expression was reduced in hIPC, 
whereas TGFB1 expression was unchanged. SMAD1-5 expression levels were also 
similar, while the inhibitory SMADs 6 and 7 were reduced (FC 0.23 and 0.48, 
respectively). RUNX2 and RUNX3, genes associated with osteogenesis and 
differentiation into mesenchymal derived tissues, were significantly lower expressed in 
hIPC.
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Fig. 23: Candidate gene clusters in hIPC and hBM-MSC 
23 a: Detection of candidate gene expression in hIPC and hBM-MSC by RT-PCR. 
Abbreviations: E-cadherin (CDH1), retinal cadherin (CDH4), fetal kidney cadherin 
(CDH6), osteoblast cadherin (CDH11), fibroblast growth factor receptor 1 and 2 
(FGFR1, FGFR2), v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(MAFB), 23 b: Heatmap of the expression pattern of the highly conserved homeobox 
gene family A (HoxA) in different individual preparations of hIPC (n=3) and hBM-
MSC (n=5). The gene names and the Affymetrix probeset IDs are shown. Red colour 
represents high expression (FC > 2), green colour represents low expression (FC < 0.5). 
23 c: Quantitative analysis of differentially expressed key genes in additional individual 
preparations of hIPC (n=5) and hBM-MSC (n=4) using qPCR. These donors are 
different from those used for the array analysis procedure thus mounting to eight and 
nine different donors for the respective primary cell populations. Abbreviations: insulin 
gene enhancer protein 1 (ISL1), v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (MAF), SRY (sex determining region Y)-box 17 (SOX17), transcription factor 
21 (TCF21), homeo box A2 (HOXA2) and homeo box A10 (HOXA10). Data are 
expressed as means with standard deviations. 
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Tab. 1: Significance analysis of microarrays (SAM) of hIPC compared to hBM-
MSC  
Gene names, detection in hBM-MSC and hIPC (absent: A; present: P), analysed 
probeset IDs, fold changes (FC) of the expression values between hIPC and hBM-MSC, 
and the gene titles are shown. Fold changes marked with ** have highly significant q-
values below 0.1. Where no difference between expression levels could be detected (ns: 
not significantly different), only the number of analysed probesets is given. 
 
Gene 
Name 
Detection 
in hBM-
MSC 
Detection 
in hIPC 
Probesets 
analysed 
Fold 
Change 
hIPC vs 
BM-MSC 
Gene Title 
Expression pattern of cadherins 
220227_at 5.93** 
CDH4 A P 
206866_at 9.13** 
cadherin 4, type 1, R-cadherin (retinal) 
CDH6 P P 3 ns cadherin 6, type 2, K-cadherin (fetal kidney) 
CDH11 P P 3 ns cadherin 11, type 2, OB-cadherin 
Genes relevant in mesenchymal versus endocrine differentiation 
FGFR1 P P 7 ns fibroblast growth factor receptor 1 
203638_s_at 0.02** 
FGFR2 P P 
208228_s_at 0.1** 
fibroblast growth factor receptor 2 
206363_at 0.03** 
MAF P P 
209348_s_at 0.05** 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog 
218559_s_at 0.04** 
MAFB P P 
222670_s_at 0.3** 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog B 
MAFK P P 226206_at 2.94** 
v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog K 
TCF21 A P 204931_at 475.32** transcription factor 21 (POD-1) 
Genes associated with EMT 
SNAI1 P P 1 ns snail homolog 1 
SNAI2 P P 1 ns snail homolog 2 
TCF3 P P 3 ns transcription factor 3 
TWIST
1 
P P 213943_at 0.31** twist homolog 1 
229404_at 2.92** TWIST
2 
P P 
1554163_at 2.07** 
twist homolog 2 (Drosophila) 
LOXL2 P P 2 ns lysyl oxidase-like 2 
205063_at 0.34** 
SIP1 P P 
3 ns 
survival of motor neuron protein interacting 
protein 1 
HMGA P P 206074_s_at 3.36** high mobility group AT-hook 1 
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Gene 
Name 
Detection 
in hBM-
MSC 
Detection 
in hIPC 
Probesets 
analysed 
Fold 
Change 
hIPC vs 
BM-MSC 
Gene Title 
210457_x_at 3.14** 
1558683_a_at 2.35** 
1558682_at 3.53** 
HMGA
2 
P P 
1561633_at 2.61** 
high mobility group AT-hook 2 
209960_at 6.48** 
210755_at 4.72** 
209961_s_at 2.98** 
210997_at 3.61** 
HGF P P 
210998_s_at 3.66** 
hepatocyte growth factor (hepapoietin A; scatter 
factor) 
TGF beta signal transduction 
224793_s_at 0.35** 
206943_at 0.37** 
TGFBR
1 
P P 
236561_at 0.39** 
transforming growth factor, beta receptor I 
TGFBR
2 
P P 2 ns 
transforming growth factor, beta receptor II 
(70/80kDa) 
TGFBR
3 
P P 204731_at ns transforming growth factor, beta receptor III 
TGFA P P 205016_at 0.13* transforming growth factor, alpha 
TGFB1 P P 203085_s_at ns transforming growth factor, beta 1 
220407_s_at 0.29** 
TGFB2 P P 
209908_s_at 0.24** 
transforming growth factor, beta 2 
SMAD
6 
P P 207069_s_at 0.23** SMAD family member 6 
SMAD
7 
P P 204790_at 0.48** SMAD family member 7 
Genes relevant in mesenchymal differentiation 
1 ns 
A 
236859_at 0.02** 
RUNX
2 
P 
P 232231_at 0.34** 
runt-related transcription factor 2 
204197_s_at 0.17** RUNX
3 
P A 
204198_s_at 0.04** 
runt-related transcription factor 3 
Genes relevant in endocrine differentiation 
ISL1 A P 206104_at 21.89** 
ISL1 transcription factor, LIM/homeodomain, 
(islet-1) 
REN A P 206367_at 302.40** renin 
AGT P P 1 ns angiotensinogen  
205357_s_at 2.35** 
AGTR1 P P 
1 ns 
angiotensin II receptor, type 1 
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C-DISCUSSION, CONCLUSIONS AND FINAL CONSIDERATIONS 
1. DISCUSSION 
Research on cell-based therapies is developing very rapidly in many fields of Medicine 
as it holds the promise to cure chronic diseases in which tissue regeneration and cell 
replacement are required.  
MSC are multipotent cells with paracrine effects and immunomodulatory properties, 
which present them as an ideal stem cell candidate for tissue engineering and 
regenerative medicine. In recent years it has come to light that MSC encompass 
plasticity that extends beyond the conventional bone, adipose, cartilage, and other 
skeletal structures, and has expanded to the differentiation of liver, kidney, muscle, skin, 
neural, and cardiac cell lineages. 
With the present studies, we intended to evaluate the potential of human MSC to be 
utilized as a cell source for cell-based therapeutic strategies of T1D and advanced T2D. 
In our first study, we investigated the potential of a well-characterized human MSC 
model (hMSC-TERT) 224, to be directed into the endocrine pathways of differentiation. 
Our results provide evidence for the potential of telomerase immortalized hMSC-TERT 
to be reprogrammed towards pancreatic endocrine phenotypes by two different 
experimental approaches. We demonstrate that hMSC-TERT display an 
endodermal pre-patterning phenotype, which may favour the endocrine pancreatic 
differentiation process. These multipotent MSC 224 respond to defined culture 
conditions with expression of several pancreatic endocrine lineage-related 
transcription factors, and also insulin and somatostatin genes. Furthermore, by 
stable overexpression of the two key pancreatic regulatory factors NGN3 and/or 
PDX1 in hMSC-TERT, we demonstrate the potential of these cells to be 
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reprogrammed by defined genetic engineering procedures similar to other 
reprogramming approaches that were reported 210, 222.  
Characteristically, hMSC-TERT cells retain a normal karyotype, can be differentiated 
into multiple mesodermal lineages 224 including an endothelial-like phenotype 249 and do 
not give rise to tumours when maintained under appropriate plating densities 250. 
The detection of the neuronal protein nestin and the cell surface antigen c-met 
reinforces the multi-lineage differentiation potential of hMSC-TERT. Nestin represents 
a characteristic marker of multi-lineage progenitor cells 251 and c-met has been proposed 
to identify adult pancreatic precursor cells 181. Previously, we found that c-met was 
expressed in 5% of freshly isolated bone marrow-derived MSC, while 80% of hMSC-
TERT express this marker, suggesting that these cells originate from a c-met+ 
subpopulation of MSC thereby displaying an endodermal pre-patterning. 
In our working hypothesis we postulated that telomerase-transduction may have 
sustained the multipotency of this clonal cell line. Validating this premise, we observed 
that treatment of hMSC-TERT with cocktail medium induces the expression of 
otherwise absent endocrine pancreatic genes including ISL1, NEUROD1, PAX4, PDX1 
and insulin. This response indicates an endodermal switching capacity, which is 
comparable to that described for human adipose-MSC treated with a similar cocktail 
medium 191. The role of soluble factors such as nicotinamide, activin-A, beta-cellulin 
and exendin-4 combined to serum-free / high glucose medium as promoters of beta cell 
differentiation has been extensively investigated in previous studies, supporting the 
strong differentiation effect of the “cocktail medium” 95, 185, 252. Importantly, using 
hMSC-TERT the achieved reprogramming output was consistently reproducible. 
This contrasts with results obtained with primary MSC, ranging from absence of 
insulin expression 212 to amelioration of diabetes after transplantation of in vitro 
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generated insulin-producing MSC 187. By this means, exploiting hMSC-TERT we 
could obviate the utilisation of heterogeneous MSC from different donors and 
different subpopulations, which unable reproducible data to be obtained 253.  
 Further investigation on cocktail-induced hMSC-TERT was not viable, in our study, 
due to phenomena of cellular apoptosis that occurred after 10 days of culture in serum 
free (SF) medium. 
In a second approach, based on the ectopic expression of the two master regulatory 
endocrine genes, PDX1 and NGN3, we analysed both, the susceptibility of hMSC-
TERT for endocrine reprogramming and specific molecular mechanisms of endocrine 
differentiation in human MSC. NGN3 protein overexpression in hMSC-TERT 
results in endogenous PDX1 gene activation, which is essential for insulin 
promoter regulation in adult beta cells. In addition, we observed that NGN3 is 
involved in the activation of PDX1 promoter, which is a major regulator of insulin 
secretion in adult beta cells. This corroborates the idea that endocrine 
differentiation of MSC in vitro follows the hierarchy model of transcription factors 
involved in maturation and maintenance of beta cells 254. Like others, we did not 
find NGN3 gene activation due to ectopic PDX1 expression in hMSC-TERT-PDX1 
cells 210. This may reflect the fact that NGN3, which is an important endocrine 
differentiation factor during development, is normally not expressed by mature beta 
cells 172. Probably, as suggested by most recent work, in adult pancreas, endogenous 
NGN3 expression is activated whenever pancreatic injury occurs in order to stimulate 
beta cell mass regeneration 86, 255. One reason why NGN3 is essential in vivo 172 86 but 
seems dispensable in vitro 210 may be the activation of alternative pathways to induce 
the endocrine differentiation cascade. Also, in our in vitro model, a transient expression 
of NGN3 cannot be excluded. 
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Other most important observation is that ectopic expression of NGN3 and/or PDX1 
could induce hMSC-TERT to express, produce and store insulin protein. However, the 
amount of insulin produced by transgenic hMSC-TERT cells was low when compared 
to biological relevant levels synthesised by mature INS-1E beta cells. There may be two 
explanations for these results. First, activation of SST, GCG and PP genes in hMSC-
TERT-derived phenotypes indicates that not every cell follows the specific 
reprogramming path towards beta cell differentiation, indicating variable differentiation 
responses to the same stimuli. Effectively, only 40% of hMSC-TERT-NGN3, 33% of 
hMSC-TERT-PDX1 and 30% of hMSC-TERT-NGN3/PDX1 were positive for insulin 
and C-peptide. Secondly, this observation may lie in the unavoidable polyclonal nature 
of generated stable cell populations, as suggested by 60% transfection efficiency in 
NGN3, PDX1 or NGN3/PDX1 new generated cell lines   
Also, the insulin secretion capacity in response to glucose stimulation is reduced, suggesting 
that the molecular mechanism of insulin secretion may not be available in these cells. In 
contrast, retroviral PDX1 overexpression induces glucose-stimulated insulin release at high 
glucose dosages (> 15 mM) in freshly isolated human bone marrow-derived MSC 210, but 
noteworthy, such an approach failed to establish insulin gene expression in MSC samples in 
5 out of 14 donors. This observation by others underscores the variability of primary MSC 
material and the need for a consistent cell culture model. 
From our findings, we presume that to establish a fully functional beta cell phenotype, 
inclusion of yet unknown experimental parameters or other (transcription) factors is 
necessary. This consideration is supported by a recent in vivo study, in which from nine 
genes important for beta cell development that were subcloned into GFP-adenoviruses, 
higher GFP+/insulin+ ratio was only achieved when PDX1 and NGN3 were 
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administered together with MAFA adenoviruses 222. Likewise, the addition of MAFA 
gene may also foster hMSC-TERT final endocrine maturation.  
From our results in this study we can conclude that hMSC-TERT constitutes a suitable 
cell model to investigate the endocrine differentiation potential of hBM-MSC. The 
usage of hMSC-TERT made it possible to analyze the molecular mechanisms of the in 
vitro differentiation pathways in a controlled and reproducible way. Nevertheless, the 
here presented data and most recent knowledge clearly indicates, that further 
investigation is required to achieve terminal endocrine maturation of adult MSC, 
suitable to be used as a promising tool for cell based-therapy of diabetes.  
 
The observations made in the previous study led us to hypothezise that, stromal derived/ 
mesenchymal stem cells (MSC) residing in distinct tissues might present different 
signatures (patterning and specification) and distinct multipotent functions.  
Therefore, in a second project, it was our objective to compare two distinct candidate 
cell populations as tools or targets for the cell-based therapy of T1D:  hBM-MSC and 
hIPC, obtained from mesodermal and endodermal derived tissues, respectively. 
Here, we could show distinct functional signatures of these two MSC populations and 
identify specific key lineage regulatory genes in hBM-MSC and hIPC. Our data also 
indicate a clear transitional state of hIPC.  
Likewise recent studies in rodents 230, 231 and in humans 226, our experiments strongly 
suggest that hIPC derive from mesenchymal cells within the pancreatic islet. This was 
shown by overlapping immunophenotypes of both cell types, similar expression levels 
of several mesenchymal markers in hIPC and hBM-MSC and a large vimentin-positive 
cell population in intact human islets. 
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In both populations, we detected genes that according to the literature have been related 
to functional stem cell characteristics like BMI1 215, HES1 256, HMGB1 257, and ABCG2 
258, which may indicate a role of both MSC populations as precursor cells. 
Nevertheless and opposite to other recent studies 228, 230, the multilineage differentiating 
capacities of these two populations are very distinct: our direct comparison of hIPC and 
their differentiation potential with the “gold standard” of MSC reveals complementary 
deficits in cell maturation of hIPC and hBM-MSC into mesenchymal and endocrine 
pathways, respectively. 
With genome-wide gene expression profiling, we identified differently expressed gene 
clusters in hIPC and hBM-MSC and unveiled a distinct functional assignment of the 
gene ontology groups in these cell types, providing evidence for a specified tissue 
signature and function of these two MSC populations.  
Moreover, a candidate gene cluster analysis revealed important aspects related to the 
mesodermal pattern, endocrine versus mesenchymal commitment and cell transition 
state of hIPC.  The vimentin+/E-cadherin- pattern and the comparable expression levels 
of other cadherin family genes showed the evident mesenchymal phenotype in both cell 
types.  
HOX genes are known regulators of patterning and migration during gastrulation with 
respect to skeleton and endoderm 259. We observed that the HOX expression pattern 
in hIPC (HoxA3-6) is strongly related to the region of foregut and pancreas 
development, while HOX genes expressed in hBM-MSC (HoxA7-13) are related to 
skeletal development 259, 260.  
Furthermore, SOX17, a marker for definitive endoderm, has only been detected in 
hIPC.  The variable expression level of SOX17 in different hIPC preparations (Fig 6c) 
suggests different stages of endodermal commitment in these cells. It has been shown 
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that SOX17 is transiently expressed during differentiation of endocrine precursors into 
islet-like cells, which makes it difficult to detect a consistent expression during the 
differentiation process 261, 262. 
The concept of sustained signatures of MSC may provide important information for 
site-specific regeneration, based on the positional memory of MSC at the site of injury 
263. On the other hand, key genes for osteogenic differentiation such as FGFR2 and 
RUNX genes 264 are repressed in hIPC, suggesting the defective mesenchymal 
differentiation potential of these cells. 
 Finally, our data present strong evidence for an intermediate phenotype of hIPC and for 
the maintenance of a positional mesenchymal signature. We found that TCF21, which is 
a key regulatory gene in MET processes, is highly induced in hIPC 248. TGFb signalling 
is also important in EMT/MET and pancreas development 265. Some components of 
TGFb signalling are repressed in hIPC, suggesting a permissive role of hIPC for islet 
cell replenishment. Recent contrasting data have traced hIPC to be either of 
mesenchymal origin 226, 230, 231 or to be a result of EMT from endocrine cells in culture 
266 232, 267. Our results emphasize the transitional state of this population.  As the 
transitions are reciprocal processes, genes involved in EMT versus MET are very 
similar 268. Thus, both mechanisms are possible, whereby their plasticity to either 
direction is more evident towards the endocrine lineage.  
This work has brought new insights to the site-specific signatures and functions of both 
MSC types suggesting distinct potential of hBM-MSC and hIPC, and raises questions as 
to the usage of various MSC populations for cell-based manipulation of islets or any 
other tissue regeneration. 
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2. CONCLUSIONS 
Due to their multipotent properties, MSC may have an almost unlimited differentiation 
potential once they have been reprogrammed. This might be achieved by specific 
culture conditions, genetic induction, silencing of key transcriptions factors or more 
recently through epigenetic modifications. 
Our projects provided new insight to the biology and function of mesenchymal stem 
cells within and outside the pancreas. Using a well-characterized human mesenchymal 
stem cell model, we investigated the molecular mechanisms of endocrine differentiation 
in BM-MSC and the potential of these cells to be directed into the endocrine pathways 
of differentiation.  
Furthermore, we compared the multilineage differentiation capacity of two MSC 
candidate cells, the hBM-MSC and the hIPC. In spite of the mesenchymal overllaping 
immunophenotype of both types of cells, differences in their stem cell character and cell 
commitment were observed. Genome-wide gene profiling analysis revealed very 
different molecular signatures, suggesting distinct mesodermal specification of the two 
MSC types and consequently distinct potential as tools and targets for beta cell 
replacement or regeneration.  
While hMSC-TERT constitute a suitable cell model for the study of endocrine 
differentiation mechanisms of multipotent hBM-MSC, hIPC population, due to its 
functional signature and transitional state of differentiation may also contribute to beta-
cell maintenance and/or replenishment by sustaining a complete mesenchymal-
endocrine transition. 
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3. CONSIDERAÇÕES FINAIS E PERSPECTIVAS FUTURAS 
O trabalho desenvolvido permite-me fundamentar algumas conclusões e discernir 
futuras linhas de actuação. 
Os resultados obtidos indicam-nos que  o potencial das populações MSC, 
nomeadamente das hIPC e hBM-MSC estão ainda por explorar. Outros estudos 
mostraram já que tanto as hIPC como as hBM-MSC quando transplantadas em ratinhos 
diabéticos levam à melhoria da glicémia nestes animais. Contudo,  a resposta insulínica 
às variações da glicémia não é satisfatória o que indica uma diferenciação endócrina 
incompleta destas células in vivo. 
 
A reprogramação genética das hIPC e hBM-MSC poderá optimizar a sua diferenciação 
endócrina. Uma linha de investigação poderá ser a indução da transição completa das 
hIPCs para células epiteliais endócrinas, identificando os mecanismos moleculares e os 
genes responsáveis pelo processo de MET. Outra linha de investigação, conhecendo 
agora o padrão de expressão de  possíveis genes determinantes da assinatura molecular 
nestas células, poderá ser o desbloquear de certos genes ( HOX6-7) ou a expressão de 
outros (TCF21). Estas abordagens poderão ser determinantes para a  reprogramação in 
vitro de hBM-MSC,  permitindo a sua utilização como fonte celular para o tratamento 
da diabetes tipo 1. 
É também urgente reflectir sobre estratégias de regeneração pancreática, 
nomeadamente, na identificação de células ou biomoléculas que influenciem a 
regeneração endógena de células beta, estimulando mecanismos de proliferação, 
diferenciação ou migração celular. 
DISCUSSION, CONCLUSIONS AND FINAL CONSIDERATIONS 
  
  
138 
Por outro lado, uma imunomodulação eficaz do processo autoimnune destruidor da 
massa de células beta, em combinação com a terapia celular, será sem dúvida 
imprescindível à cura da diabetes tipo 1. 
Este é pois um campo de investigação que liga a medicina à investigação básica e se 
constitui um exemplo de Medicina translaccional por excelência. Devido aos avanços 
conseguidos pelos inúmeros grupos de investigadores, à pressão económica actual e ao 
impacto dos media na sociedade, existe um risco de oferta de terapias celulares 
curativas sem base científica rigorosa. São prova disso os centros médicos, de 
transplante de células estaminais já existentes na Europa, para o tratamento das mais 
variadas patologias, cuja idoneidade é questionável. 
 
É minha firme intenção prosseguir na investigação das células estaminais adultas, 
candidatas à utilização em estratégias de terapia celular da diabetes tipo 1.  
Procurando encontrar respostas a inúmeras questões surgidas ao longo deste trabalho e 
com a experiência e conhecimentos que ele me permitiu acumular, o passo natural 
seguinte é elaborar novos projectos de investigação visando esta e outras vertentes da 
terapia celular da diabetes.  
Cito como exemplo de estudos actualmente propostos a entidades financiadoras:  
1) Novos métodos de imagem para a detecção de células transplantadas em humanos 
(colaboração com o instituto de física e departamento de biologia de células estaminais 
da Universidade de Würzburg, proposto para uma bolsa de projecto Europeu  Marie 
Curie); 
2) O estudo das células progenitoras expressoras do gene ISL1, (colaboração com o 
Instituto Gulbenkian Ciencia, proposto à FCT;   
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3) O potencial dos análogos do glucagon-like-peptide 1 (GLP1) como regeneradores das 
células endócrinas na diabetes tipo 1 ( proposto a 2 empresas farmacêuticas); 
 4) Estudos para a avaliação do papel da Vit D como imunomodulador na diabetes tipo 1 
(colaboração com o departamento biologia de células estaminais da Universidade de 
Würzburg proposto para uma bolsa de projecto Europeu  Marie Curie). 
É minha expectativa que o desenvolvimento destas linhas de investigação contribua 
para: 
 a) Compreender as potencialidades dos tecidos e orgãos humanos, como possíveis 
fontes de células utilizáveis na regeneração e/ou substituição celular , para o tratamento 
definitivo da diabetes tipo 1 e situções avançadas da diabetes tipo 2; 
b) Desenvolver técnicas de detecção de células transplantadas sem risco de toxicidade 
humana; 
c) Compreender o papel de determinadas biomoléculas envolvidas em mecanismos de 
imunomodulação essencial à prevenção e regeneração da massa de células beta do 
pâncreas endócrino. 
É minha esperança contribuir para o desenvolvimento, em Portugal, da medicina 
translacional criando um Grupo de Trabalho neste campo da investigação e motivando 
jovens médicos a investir na sua formação nestas áreas tão fascinantes quanto 
inovadoras. 
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Suppl. Table 1: Primer Sequences and Conditions of PCR used in Project 1 and 2 
Genes 
sense primer 
antisense primer      5’-3’ 
Annealing Temperature 
(Cº) 
Cycles 
Product 
size 
ABCG2 
GAAACCTGGTCTCAACGC 
TGGAGTCTGCCACTTTAT 
50 35 317 bp 
BMI1 
TCGGAAAGTAAACAAAGACAAAGAG 
TAGGCAAACAAGAAGAGGTGGA 
52 35 389 bp 
CDH1 
ACTGGACCATTCAGTACAAC 
GAACCGCTTCCTTCATAG 
54 30 610 bp 
CDH11 
GGGGAGGAAGTAGGAAGAGTG 
ATACCTTATCGGGCTGTTGG 
60 38 408 bp 
CDH4 
CAAAGACAACACGGCGGGAATC 
CGGGCACAATGTCCCTTCGTAA 
66 38 458 bp 
CDH6 
ATTATCAGTATGTGGGCAAGTT 
GACATCAGACATTTCAGGGAC 
60 38 314 bp 
C-MET 
CAATGTGAGATGTCTCCAGC 
CCTTGTAGATTGCAGGCAGA 
57 35 560 bp 
EF1alpha 
AGGTGATTATCCTGAACCATCC 
AAAGGTGGATAGTCTGAGAAGC 
56 35 235 bp 
FGFR1 
CGGGACATTCACCACATC 
CCACTGGCACCACCTATCT 
56 27 1037 bp 
FGFR2 
CTCCTCCATGAACTCCAAC 
CTGGCTTATCCATTCTGTG 
53 38 872 bp 
FNT 
ACAGTGGCAGAAGGAATA 
AGAACTCTAAGCTGGGTC 
50 35-38 334bp 
GLUC 
ACTTTGTGGCTGGATTATTTGT 
GTTTGGCAATGTTATTCCTGTT 
52 38 258 bp 
GCK 
CTGGTGAAGGTGGGAGAAG 
GCAGGAGATCATCGTGGC 
55 38 312 bp 
GLUT2 
TCCAGCTACCGACAGCCTATTC 
AGATGGCACAAACAAACATCCC 
55 38 257 bp 
HES1 
GTCAACACGACACCGGATAA 
AGCGGGTCACCTCGTTCA 
57 35 310 bp 
HMGB1 
TCCATTGGTGATGTTGCGAAGA 
TCAGCCTTGACAACTCCCTTTT 
53 35 176 bp 
HOXB5 
TTCACCGAAATAGACGAGG 
AAGACCTAAGACCAAACGAAA 
53 40 893 bp 
INS GCAGCCTTTGTGAACCAACACC 58 38 209 bp 
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TGTTCCACAATGCCACGCTTC 
ISL1 
CAGGTTGTACGGGATCAAATGC 
GATGCTTCGCTTCTTGTCCTTG 
60 35 508 bp 
MAF 
ATAGTGGGAGTAGCAAACAAAT 
AAGATCAAACGCAGCGTAAA 
56 38 156 bp 
MAFB 
AGCCCGACCGAACAGAAGAC 
TGATGGTGGTGGTGGTGAGC 
62 38 188 bp 
MEIS1 
ACCAGCCCTCTTGGAACA 
AGTCCCGTGTCTTGTGCC 
57 35 315 bp 
MEIS2 
CAACCTCAACCCACTCAG 
TGCCCATTCCACTCATAG 
53 35 400 bp 
MMP2 
CCTGATGTCCAGCGAGTG 
TCAGCAGCCTAGCCAGTCG 
54 35-38 297 bp 
NESTIN 
AGAGGGGAATTCCTGGAG 
CTGAGGACCAGGACTCTCTA 
58 35 495 bp 
NEUROD1 
CAGGCGCATAGACCTGCTA 
TTCTTGTCTGCCTCGTGCT 
54 38 312 bp 
NGN3 
CTCAACTCGGCACTGGACG 
CAGGGAGAAGCAGAAGGAACAA 
60 35 473 bp 
OCT1 
AATCCGTCAGAAACCAGTA 
GCAGGCGTCAAAGTAAGC 
52 35 344 bp 
P4HA1 
GTTGGAGCTAGTGTTTGG 
CTGCCTTGTCTTCTGTGA 
49 35-38 437 bp 
PAX4 
ACCGAGTCCTGCGGGCATTAC 
TGCCCACGCTGGAACTCTTTCT 
60 38 210 bp 
PAX6b 
AATTCTGGGCAGGTATTACGA 
CAGCCATCTTGCGTAGGTT 
56 35 366 bp 
PDX1 
CCCATGGATGAAGTCTACC 
GTCCTCCTCCTTTTTCCAC 
55 35 262 bp 
PP 
GTGTACCCAGGGGACAATG 
CGTAGGAGACAGAAGGTGGC 
53 35 207 bp 
SNAI2 
TTCCAGACCCTGGTTGCT 
CATTTGGCTTCGGAGTGA 
53 35-38 283 bp 
STT 
TTTAGGAGCGAGGTTCGG 
TCAGGTTCCAGGGCATCA 
54 38 306 bp 
TCF21 
TTGGAATGTGACGGGTTGAA 
TGGGCTCTATCCCTCTGGTA 
58 38 553 bp 
THY1 
CCCGAACCAACTTCACCA 
GGCTTCCTGTCTCCTCCAT 
54 35-38 291 bp 
VIM 
AGCTTCCTGTAGGTGGCA 
CAGTAGCGAGAAGAATGGT 
52 35-38 356bp 
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Legend suppl Tab. 1:  
Names of the amplified genes, sequences of the primer pairs, annealing temperatures, 
number of cycles and the size of the corresponding PCR product are shown (ATP 
binding cassette group 2 (ABCG2), polycomb group repressor gene 1 (Bmi1), E-
cadherin (CDH1), retinal cadherin (CDH4), fetal kidney cadherin (CDH6), osteoblast 
cadherin (CDH11), hepatocyte growth factor receptor (C-MET), elongation factor 1 
alpha (EF1alpha), fibroblast growth factor receptor 1 and 2 (FGFR1, FGFR2), 
Fibronectin (FNT), glucagon (GLUC), glucokinase (GCK), glucose transporter member 
2 (GLUT2), hairy enhancer of split 1 (Hes1), high mobility group box 1 (Hmgb1), 
homeobox b 5 (HOXb5), insulin (INS), insulin gene enhancer protein 1 (ISL1), v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog (MAF), v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB), meis homeobox 1 
and 2 (MEIS1, MEIS2), matrix metalloproteinase 2 (MMP2), POU class 2 homeobox 1 
(OCT1), neurogenic differentiation 1 (NEUROD1), neurogenin 3 (NGN3), prolyl 4-
hydroxylase, alpha I subunit (P4HA1), paired box 4 (PAX4), paired box 6 (PAX6b), 
pancreatic and duodenal homeobox 1 (PDX1), pancreatic polypeptide (PP), snail 2 
(SNAI2), somatostatin (STT), transcription factor 21 (TCF21), Thy1 (THY1), vimentin 
(VIM).  
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Suppl. Tab. 2: Expression of stemness-related genes in hIPC compared to hBM-MSC. 
Gene 
Name 
Probesets on 
U133Plus2 
Array 
Detection 
in hBM-
MSC 
Detection 
in hIPC 
Affymetrix 
Probeset ID 
Fold 
Change 
hIPC vs 
BM-
MSC 
Gene Title 
Stemness-related Genes 
ABCG2 1 P P 209735_at ns 
ATP-binding cassette, sub-
family G (WHITE), 
member 2 
BMI1 1 P P 202265_at ns 
B lymphoma Mo-MLV 
insertion region (mouse) 
203394_s_at 4.39 
HES1 2 P P 
203395_s_at 3.5 
hairy and enhancer of split 
1, (Drosophila) 
200679_x_at 
200680_x_at 
214938_x_at 
224731_at 
224734_at 
HMGB1 6 P P 
216508_x_at 
ns high-mobility group box 1 
HOXB2 1 P P 205453_at 2.5** homeobox B2 
205601_s_at 8.75** 
HOXB5 2 P P 
205600_x_at 7.07** 
homeobox B5 
POU2F1 3 P P 206789_s_at ns 
POU domain, class 2, 
transcription factor 1 
PAX8 8 P P 121_at ns paired box gene 8 
242172_at 3.89** 
1559477_s_at 3.18** MEIS1 3 P P 
204069_at 3.44** 
Meis1, myeloid ecotropic 
viral integration site 1 
homolog (mouse) 
MEIS2 1 P P 207480_s_at ns 
Meis1, myeloid ecotropic 
viral integration site 1 
homolog 2 (mouse) 
 
Legend suppl. Tab. 2: Gene names, detection in hBM-MSC and hIPC (absent: A; 
present: P), analysed probeset IDs, fold changes (FC) of the expression values between 
hIPC and hBM-MSC, and the gene titles are shown. Fold changes marked with ** have 
highly significant q-values below 0.1. Where no difference between expression levels 
could be detected, the number of analysed probesets is given (ns: not significantly 
different). 
